Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 4604. Отображено 100.
05-04-2012 дата публикации

In Vitro Generation of Myeloid Derived Suppressor Cells

Номер: US20120082688A1
Принадлежит: Mount Sinai School of Medicine

The invention relates to methods of isolating, culturing, and differentiating myeloid derived suppressor cells (MD-SCs) from embryonic stem (ES) cells and hematopoietic stem cells (HSCs). In certain embodiments, the invention relates to methods and compositions for producing MDSCs from ES cells and HSCs using a combination of factors including macrophage colony-stimulating factor (M-CSF).

Подробнее
10-05-2012 дата публикации

Smac mimetec

Номер: US20120115922A1
Принадлежит: TETRALOGIC PHARMACEUTICALS CORP

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Подробнее
16-08-2012 дата публикации

Adipose-derived stem cells and lattices

Номер: US20120208274A1
Принадлежит: Individual

The present invention provides adipose-derived stem cells (ADSCs), adipose-derived stem cell-enriched fractions (ADSC-EF) and adipose-derived lattices, alone and combined with the ADSCs of the invention. In one aspect, the present invention provides an ADSC substantially free of adipocytes and red blood cells and clonal populations of connective tissue stem cells. The ADSCs can be employed, alone or within biologically-compatible compositions, to generate differentiated tissues and structures, both in vivo and in vitro. Additionally, the ADSCs can be expanded and cultured to produce molecules such as hormones, and to provide conditioned culture media for supporting the growth and expansion of other cell populations. In another aspect, the present invention provides a adipose-derived lattice substantially devoid of cells, which includes extracellular matrix material from adipose tissue. The lattice can be used as a substrate to facilitate the growth and differentiation of cells, whether in vivo or in vitro, into anlagen or even mature tissues or structures.

Подробнее
03-01-2013 дата публикации

Multipotent adult stem cell population

Номер: US20130004464A1
Автор: Bernardo Nadal-Ginard
Принадлежит: Individual

The present invention relates to the identification, isolation, expansion and characterization of a specific type of adult stem cell. These adult stem cells are characterised in that they naturally express many of the markers of totipotency, which have hitherto generally been limited to embryonic cell populations. The cells of the invention display an unprecedented capacity for multipotency; they are able to differentiate into cell types of mesodermal, endodermal and ectodermal origin. These adult stem cells may be used as therapeutic agents including, without limitation, for the regeneration of tissue, particularly for regeneration of damaged cardiac tissue, such as myocardium.

Подробнее
10-01-2013 дата публикации

SMAC Mimetic

Номер: US20130012564A1
Принадлежит: TETRALOGIC PHARMACEUTICALS CORP

A SMAC mimetic and pharmaceutical compositions thereof and methods of use.

Подробнее
24-01-2013 дата публикации

Multipotent adult stem cell population

Номер: US20130023046A1
Автор: Bernardo Nadal Ginard
Принадлежит: Individual

The present invention relates to the discovery of a population of non-germ adult stem cells that can be found in tissue from non-embryonic mammals, including at least mouse, rat, pig and human. These adult stem cells, which are present within the post-natal individual at all ages from infancy to senescence have a phenotype and developmental potential that is different from stem cell types, embryonic and adult, that have so far been described.

Подробнее
24-01-2013 дата публикации

Beta-cell replication promoting compounds and methods of their use

Номер: US20130023491A1

In the invention provides for a method of stimulating or increasing β-cell replication or growth, by contacting a β-cell with an inhibitor of adenosine kinase (ADK), an inhibitor of S-Adenosylhomocysteine hydrolase (SAHH) or an activator of AMP activated protein kinase (AMPK).

Подробнее
01-08-2013 дата публикации

Induced dendritic cell compositions and uses thereof

Номер: US20130195919A1
Принадлежит: Harvard College

The invention provides, for example, compositions comprising induced tolerogenic dendritic cells which are capable of suppressing an antigen specific T cell-mediated immune response, and to methods of making and using the same. The invention also provides compositions comprising induced immunogenic dendritic cells and methods of making and using them.

Подробнее
17-10-2013 дата публикации

Insulin producing cells derived from pluripotent stem cells

Номер: US20130273013A1
Принадлежит: KADIMASTEM Ltd

A method of generating islet cells from pluripotent stem cells is disclosed. The method comprises: (a) culturing the pluripotent stem cells in a differentiation medium so as to differentiate the pluripotent stem cells into endoderm cells; and (b) culturing the endoderm cells in a medium comprising at least one growth factor, a cAMP inducer and retinoic acid (RA), said at least one growth factor being selected from the group consisting of FGF10, bFGF and FGF7 so as to generate further differentiated cells; and (c) culturing the further differentiated cells in a medium comprising a maturation factor selected from the group consisting of nicotinamide, GLP-1 and exendin 4, thereby generating islet cells from pluripotent stem cells. Further methods of generating islet cells are also disclosed, isolated cell populations comprising same and uses thereof.

Подробнее
14-11-2013 дата публикации

Modalities for the treatment of degenerative diseases of the retina

Номер: US20130302426A1
Принадлежит: Advanced Cell Technology Inc

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells.

Подробнее
28-11-2013 дата публикации

Method for stem cell differentiation in vivo by delivery of morphogenes with mesoporous silica and corresponding pharmceutical active ingredients

Номер: US20130315962A1
Принадлежит: Nanologica AB

A pharmaceutical active ingredient for cell differentiation to alleviate cell and cell-related deficiencies in mammals comprising porous silica containing a releasable agent capable of contributing to a cell environment conducive for stem cell differentiation in co-implanted stem cells and/or in endogenous stem cells.

Подробнее
07-01-2016 дата публикации

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

Номер: US20160002593A1
Принадлежит: Genentech, Inc.

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. 1. A method of culturing a cell comprising a nucleic acid encoding a polypeptide , wherein the method comprises the step of contacting the cell with a cell culture medium comprising hypotaurine or an analog or precursor thereof , wherein the cell culture medium comprising the hypotaurine or an analog of precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell as compared to the color intensity of a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.2. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by at least about 0.1% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.3. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by about 5% to about 50% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.43. The method of any one of - claims 1 , wherein the cell culture medium comprises the hypotaurine or an analog or precursor thereof at a concentration of at least about 0.0001 mM.5. The method of claim 4 , wherein the cell culture medium comprises the ...

Подробнее
05-01-2017 дата публикации

Methods relating to pluripotent cells

Номер: US20170002314A1
Принадлежит: Vcell Therapeutics Inc

The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material.

Подробнее
05-01-2017 дата публикации

METHODS OF GENERATING NATURAL KILLER CELLS

Номер: US20170002322A1
Принадлежит: Anthrogenesis Corporation

Provided herein are methods of producing natural killer cells using a two-step expansion and differentiation method. Also provided herein are methods of suppressing tumor cell proliferation, of treating individuals having cancer or a viral infection, comprising administering the NK cells produced by the method to an individual having the cancer or viral infection. 1. A method of producing a population of activated natural killer (NK) cells , comprising:(a) seeding a population of hematopoietic stem or progenitor cells in a first medium comprising interleukin-15 (IL-15) and, optionally, one or more of stem cell factor (SCF) and interleukin-7 (IL-7), wherein said IL-15 and optional SCF and IL-7 are not comprised within an undefined component of said medium, such that the population expands, and a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; and(b) expanding the cells from the step (a) in a second medium comprising interleukin-2 (IL-2), to produce a population of activated NK cells.2. A two-step method of producing a population of activated natural killer (NK) cells , wherein a first step of said method comprises expanding a population of hematopoietic stem or progenitor cells in a first medium comprising one or more of stem cell factor (SCF) , interleukin-7 (IL-7) and interleukin-15 (IL-15) , and wherein said SCF , IL-7 and IL-15 are not comprised within an undefined component of said medium , and wherein a plurality of hematopoietic stem or progenitor cells within said population of hematopoietic stem or progenitor cells differentiate into NK cells during said expanding; andwherein a second step of said method comprises expanding the cells from the first step in a second medium comprising interleukin-2 (IL-2), to produce activated NK cells.3. The method of claim 1 , wherein the first medium further comprises one or more of Fms-like-tyrosine ...

Подробнее
05-01-2017 дата публикации

MEDIUM FOR THE PROTEIN-FREE AND SERUM-FREE CULTIVATION OF CELLS

Номер: US20170002392A1
Принадлежит:

A medium is described for the protein-free and serum-free cultivation of cells, especially mammalian cells, whereby the medium contains a proportion of soy hydrolysate. 1. An animal protein-free and serum-free cell culture medium , the medium comprising a soy hydrolysate having a total nitrogen content of between 7.6% and 11.4% , and the medium comprising0.001-1 g/L L-asparagine,0.001-1 g/L L-cysteine,0.001-1 g/L L-cystine,0.001-1.5 g/L L-proline,0.001-1 g/L L-tryptophan, and0.05-1 g/L L-glutamine.2. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium comprises an endotoxin content of <500 U/g.3. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium comprises more than 10 wt. % ultrafiltered soy hydrolysate based on the total dry weight of the medium claim 1 , and wherein at least 40% of the soy hydrolysate has a molecular weight of ≦500 daltons.4. The animal protein-free and serum-free cell culture medium of claim 3 , wherein at least 50% of the soy hydrolysate has a molecular weight of ≦500 daltons.5. The animal protein-free and serum-free cell culture medium of claim 3 , wherein at least 55% of the soy hydrolysate has a molecular weight of ≦500 daltons.6. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium contains ultrafiltered soy hydrolysate.7. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the medium comprises an amino acid.8. The animal protein-free and serum-free cell culture medium of claim 7 , wherein the amino acid is selected from the group consisting of L-asparagine claim 7 , L-cysteine claim 7 , L-cystine claim 7 , L-proline claim 7 , L-tryptophan claim 7 , L-glutamine and mixtures thereof.9. The animal protein-free and serum-free cell culture medium of claim 1 , wherein the animal protein-free and serum-free cell culture medium further comprises: 1 to 100 g/L synthetic minimal medium; 0.05-1 g/L glutamine ...

Подробнее
02-01-2020 дата публикации

CRUSHED STEM CELL EXTRACT (SHELLED STEM CELL) MANUFACTURING METHOD USING MASS CULTURE MEDIUM COMPOSITION METHOD AND CONSTITUENT 3-LOW EXTRACTING METHOD AND A TREATING COMPOSITION FOR ANTI-INFLAMMATORY AND A TREATING COMPOSITION FOR CELL REGENERATION

Номер: US20200002678A1
Принадлежит: Tiara Stem Cell Institute

Disclosed is a method of manufacturing a medium composition for cell culture, and a method of manufacturing a crushed stem cell extract using a method of manufacturing a medium composition for cell culture and a 3-low extracting method of active ingredients of a stem cell. The medium composition for cell culture includes a basal medium; a hyaluronic acid; and an additive composition. According to an embodiment, when active ingredients of a stem cell are extracted, a stem cell is crushed at a 3-low circumstance of low temperature, low pressure, a hypotonic circumstance. 1. A method of manufacturing a medium composition for cell culture , comprising:a basal medium;a hyaluronic acid; andan additive composition.2. The method according to claim 1 , wherein the additive composition comprises at least one of glycine claim 1 , histidine claim 1 , isoleucine claim 1 , methionine claim 1 , phenylalanine claim 1 , proline claim 1 , hydroxyproline claim 1 , serine claim 1 , threonine claim 1 , tryptophan claim 1 , tyrosine claim 1 , valine claim 1 , bFGF claim 1 , EGF claim 1 , VEGF claim 1 , KGF claim 1 , HGF claim 1 , TGF claim 1 , vitamin C claim 1 , vitamin B1 claim 1 , vitamin B12 claim 1 , vitamin E claim 1 , selenium claim 1 , and transferrin.3. The method according to claim 1 , wherein the basal medium comprises one of DMEM (Dulbecco's Modified Eagle's Medium) claim 1 , MEM (Minimal Essential Medium) claim 1 , BME (Basal Medium Eagle) claim 1 , RPMI 1640 claim 1 , F-10 claim 1 , F12 claim 1 , DMEM-F12 claim 1 , α-MEM (α-Minimal Essential Medium) claim 1 , G-MEM (Glasgow's Minimal Essential Medium) claim 1 , IMDM (Iscove's Modified Dulbecco's Medium) claim 1 , MacCoy's 5A medium claim 1 , AmnioMax claim 1 , AminoMax II complete Medium claim 1 , Chang's Medium MesemCult-XF Medium.4. The method according to claim 2 , wherein claim 2 , in the additive composition claim 2 ,a concentration of the hyaluronic acid to the medium composition is 10 μg/Ml,a concentration of the ...

Подробнее
03-01-2019 дата публикации

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

Номер: US20190002822A1
Принадлежит: Genentech, Inc.

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. 163-. (canceled)65. The method of claim 64 , wherein the cell culture medium comprising the one or more of components (a)-(g) reduces the color intensity of the composition comprising the recombinant polypeptide produced by the cells by at least about 0.1% as compared to the composition comprising the recombinant polypeptide produced by the cell cultured in a cell culture medium that does not comprise the one or more of components (a)-(g).66. The method of claim 64 , wherein the cell culture medium comprising the one or more of components (a)-(g) reduces the color intensity of the composition comprising the recombinant polypeptide produced by the cells by about 5% to about 50% as compared to the composition comprising the recombinant polypeptide produced by the cell cultured in a cell culture medium that does not comprise the one or more of components (a)-(g).67. The method of claim 64 , wherein the cell culture medium comprises the one or more components (a)-(g) in an amount selected from the group consisting of:(a) hypotaurine at a concentration from at least about 0.0001 mM;(b) s-carboxymethylcysteine at a concentration from at least about 0.0001 mM;(c) carnosine at a concentration from at least about 0.0001 mM;(d) anserine at a concentration from at least about 0.0001 mM;(e) butylated hydroxyanisole at a concentration from at least about 0.0001 mM;(f) lipoic acid at a concentration from at least about 0.0001 mM; and(g) quercitrin hydrate at a concentration from at least about 0.0001 mM.68. The method of claim 67 , wherein the cell culture medium comprises hypotaurine at a concentration from about 2.0 mM to about 50.0 mM.69. The method of claim 67 , wherein the cell culture medium comprises ...

Подробнее
01-01-2015 дата публикации

Method for differentiating stem cells into neurons

Номер: US20150004701A1

The present invention relates to a method for differentiating stem cells into neurons, and is characterized in that stem cells are treated with a culture additive comprising lipoic acid, albumin, hydrocortisone, and insulin after culturing for differentiation into neurons. Since the neurons produced according to the method for producing neurons of the present invention express nestin, neuroD1, neuron-specific enolase (NSE), neurofilament (NF), tau, microtubule-associated protein 2 (MAP2), and doublecortin (DCX), just as normal mature neurons do, the neurons of the present invention can be effectively used in various therapeutic agents for neurons and as cell origins for an in vitro study system.

Подробнее
14-01-2021 дата публикации

PANCREATIC CELLS FOR TREATING DIABETES AND METHODS OF GENERATING THE SAME

Номер: US20210008122A1
Автор: Rust William L.
Принадлежит: Seraxis, Inc.

The present disclosure provides cell-based compositions for treating diabetes, methods for identifying cells that preferentially differentiate into endoderm cells, and methods for preparing insulin-producing pancreatic cells, as well as related methods of use for treating diseases related to insulin deficiency. 1. A method of producing mammalian insulin-secreting cells , comprising:a. culturing mammalian stem cells in adhesion, thereby allowing the mammalian stem cells to spontaneously form three-dimensional structures; andb. culturing of the three-dimensional structures in suspension;wherein the culturing steps comprise at least a 20-day exposure to retinoic acid and cyclopamine, and do not comprise exposing the stem cells of three-dimensional structures to Wnt3A.2. The method of claim 1 , wherein the mammalian stem cells are human stem cells.3. The method of claim 1 , wherein the mammalian stem cells are non-human primate stem cells.4. The method of claim 1 , wherein the mammalian stem cells were derived from a cell line.5. A method of producing insulin-secreting cells claim 1 , comprising:a. culturing mammalian stem cells on an adhesive substrate in a first medium comprising Activin-A and Wortmannin, wherein the mammalian stem cells are not exposed to Wnt3a;b. further culturing the cells in at least one additional medium comprising retinoic acid and cyclopamine; andc. transferring the cells to a suspension culture when the cells form three-dimensional cell structures;wherein the cells are exposed to retinoic acid and cyclopamine for at least 20 days.6. The method of claim 5 , wherein the mammalian stem cells form three-dimensional structures when cultured on the adhesive substrate.7. The method of claim 5 , wherein the mammalian stem cells are human stem cells.8. The method of claim 5 , wherein the mammalian stem cells are non-human primate stem cells.9. (canceled)10. (canceled)11. (canceled)12. (canceled)13. (canceled)14. (canceled)15. (canceled)16. (canceled)17 ...

Подробнее
12-01-2017 дата публикации

Method Of Differentiation From Stem Cells To Hepatocytes

Номер: US20170009203A1
Принадлежит: JAPAN HEALTH SCIENCES FOUNDATION

Disclosed are: a gene transduction method for use in the induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes effectively; stem cells into each of which a gene useful for the induction of the differentiation into hepatocytes is introduced; and hepatocytes produced from stem cells each having the gene introduced therein. A specific gene can be introduced into stem cells such as ES cells or iPS cells using an adenovirus vector. The effective induction of the differentiation into hepatocytes can be achieved by introducing the gene. Specifically, the effective induction of the differentiation of stem cells such as ES cells or iPS cells into hepatocytes can be achieved by introducing at least one gene selected from HEX gene, HNF4A gene, HNF6 gene and SOX17 gene into the stem cells.

Подробнее
11-01-2018 дата публикации

A DIRECT CONVERSION METHOD OF HUMAN FIBROBLASTS INTO NEURAL STEM CELLS USING SMALL MOLECULES

Номер: US20180010094A1
Принадлежит:

The present invention relates to a method of converting human fibroblasts into neural stem cells, and more particularly, to a method of directly converting human fibroblasts into neural stem cells using only a combination of small-molecule compounds without any introduction of a foreign gene, and to the use of the neural stem cells. The method of directly converting human fibroblasts into neural stem cells using only small-molecule compounds without any introduction of a foreign gene makes it possible to obtain genetically stable neural stem cells in an amount sufficient for use in cell therapy by deriving them from human fibroblasts. The neural stem cells obtained according to the method of the present invention can differentiate into functional neural cells and are not tumorigenic. Thus, these neural stem cells are useful as cellular therapeutic agents for treatment of brain diseases. 1. A method for producing neural stem cells , the method comprising:culturing human fibroblasts in a medium comprising Thiazovivin, Valproic acid, Purmorphamine, A8301, SB431542 and CHIR99021.2. The method of claim 1 , wherein the medium further comprises either DZNep (Deazaneplanocin A) or 5-AZA.3. The method of claim 2 , wherein the medium further comprises one or more small-molecule compounds selected from the group consisting of PD0325901 claim 2 , ascorbic acid claim 2 , PS48 claim 2 , forskolin claim 2 , and tranylcypromine.4. The method of claim 1 , wherein the medium is a DMEM/F12 containing N2 claim 1 , B27 claim 1 , bFGF claim 1 , and EGF.5. The method of claim 1 , wherein the human fibroblasts are cultured for 10-15 days.6. The method of claim 1 , further comprising the steps of:forming spheres by subculturing and then suspension culturing the human fibroblasts; andadherent culturing the formed spheres and then suspension culturing the adherent cultured spheres.7. The method of claim 6 , wherein the suspension culture and the adherent culture are each performed for 7-10 ...

Подробнее
10-01-2019 дата публикации

Methods for fermentative production of massoia lactone

Номер: US20190010444A1
Автор: Lianghui Ji, Si Te NGOH
Принадлежит: Temasek Life Sciences Laboratory Ltd

The present invention relates to the field of fermentation biotechnology, more particularly to methods for the fermentative production of massoia lactone by Aureobasidium species.

Подробнее
10-01-2019 дата публикации

Method for Culturing Limbal Stem Cells by Using Amniotic Membrane Slide Scaffold

Номер: US20190010454A1
Принадлежит:

The present invention relates to a method for culturing limbal tissues on an amniotic membrane slide scaffold, thereby enabling the proportion of limbal stem cells in a limbal tissue-derived epithelial cell sheet to be effectively increased, and the same to be cultured. According to the present invention, the proportion of limbal stem cells in in a limbal tissue-derived epithelial cell sheet can be stably and rapidly increased, and thus the success rate can be increased when in limbal tissue-derived epithelial cell sheets are transplanted into a patient with limbal stem cell deficiency. 1. A method for culturing limbal stem cells , comprising:covering a slide glass scaffold with an epithelial cell-removed amniotic membrane for fixation; andculturing limbal tissue on the fixed amniotic membrane.2. The method according to claim 1 , wherein each of the width and length of the amniotic membrane is 28 to 35 mm.3. The method according to claim 1 , wherein epithelial cells of the amniotic membrane are removed using 4 to 6 M urea.4. The method according to claim 1 , wherein each of the width and length of the slide glass is 18 to 28 mm.5. The method according to claim 1 , wherein the limbal tissue is cultured in DMEM/F12(1:1) supplemented with human serum claim 1 , an epithelial cell growth factor (EGF) claim 1 , dimethyl sulfoxide (DMSO) claim 1 , insulin transferrin selenium (ITS) and 0-phosphoethanolamine.6. The method according to claim 5 , wherein the human serum is a human albumin serum claim 5 , and added at 4 to 6% (v/v) of the entire medium.7. The method according to claim 1 , wherein the limbal tissue is cultured for 10 to 14 days.8. The method according to claim 7 , wherein claim 7 , when the limbal tissue is grown to 85 to 95% of the area of the scaffold claim 7 , the limbal tissue is classified as a transplant for a patient. The present invention relates to a method for culturing limbal stem cells using an amniotic membrane slide scaffold. More particularly, ...

Подробнее
09-01-2020 дата публикации

Enrichment of Listeria

Номер: US20200010871A1
Принадлежит: Merck Patent GmBH

The present invention relates to a method, a medium and a kit for the enrichment and detection of species, especially . The medium is an enrichment medium comprising C12 to C16 fatty acids and/or derivatives thereof. 1ListeriaListeria.. A method comprising enriching and optionally detecting in a sample in the presence of other Gram-positive bacteria , by incubating the sample in a culture medium comprising one or more Cto Calkyl acids and/or alcohols , or one or more salts or anhydrides thereof , and optionally detecting2ListeriaListeria monocytogenes.. The method according to whereby the enriched is3. The method according to whereby the incubation takes place at a temperature of 25 to 40° C.4. The method according to whereby the incubation is performed fora time of 10 to 60 hours.5. The method according to whereby after incubation claim 1 , detection is done by growing in a selective culture medium claim 1 , by molecular biological methods or by immunological technologies.6. The method according to whereby the alkyl acids and/or alkyl alcohols and/or derivatives thereof are Cto Cphosphonic acids claim 1 , Cto Cfatty acids claim 1 , Cto Cdicarboxylic acids claim 1 , Cto Calcohols or salts thereof.7. A culture medium comprising Cto Calkyl acids and/or alkyl alcohols and/or derivatives thereof.8. The culture medium according to whereby the alkyl acids and/or alkyl alcohols and/or derivatives thereof are Cto Cphosphonic acids claim 7 , Cto Cfatty acids claim 7 , Cto Cdicarboxylic acids claim 7 , Cto Calcohols or salts thereof.9. The culture medium according to comprising the Cto Calkyl acids and/or alkyl alcohols and/or derivatives thereof in concentrations of 10-1000 mg/L.10. The culture medium according to comprising a selective agent which is not a Cto Calkyl acid and/or an alkyl alcohol and/or a derivative thereof.11. The culture medium according to whereby the selective agent reduces or inhibits the growth of Gram-negative bacteria.12. The culture medium according ...

Подробнее
21-01-2021 дата публикации

CELL CULTURE COMPOSITIONS WITH ANTIOXIDANTS AND METHODS FOR POLYPEPTIDE PRODUCTION

Номер: US20210017488A1
Принадлежит: Genentech, Inc.

Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides, produced by the methods herein are also provided. 1. A method of culturing a cell comprising a nucleic acid encoding a polypeptide , wherein the method comprises the step of contacting the cell with a cell culture medium comprising hypotaurine or an analog or precursor thereof , wherein the cell culture medium comprising the hypotaurine or an analog of precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell as compared to the color intensity of a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.2. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by at least about 0.1% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.3. The method of claim 1 , wherein the cell culture medium comprising the hypotaurine or an analog or precursor thereof reduces the color intensity of a composition comprising the polypeptide produced by the cell by about 5% to about 50% as compared to a composition comprising the polypeptide produced by the cell cultured in a cell culture medium that does not comprise the hypotaurine or an analog or precursor thereof.4. The method of any one of - claim 1 , wherein the cell culture medium comprises the hypotaurine or an analog or precursor thereof at a concentration of at least about 0.0001 mM.5. The method of claim 4 , wherein the cell culture medium comprises the ...

Подробнее
16-01-2020 дата публикации

Method For Producing Induced Pluripotent Stem Cells

Номер: US20200017837A1
Автор: AOI Takashi

Provided is a method of generating iPS cells. Specifically, provided is a method of generating iPS cells having a rearranged γδ-TCR gene. Also provided is a cell population including the generated iPS cells. The method includes stimulating collected blood cells with IL-2 and a bisphosphonate, and then introducing cell reprogramming factors through use of a Sendai virus (SeV) vector. According to the method of the present invention, iPS cells having a rearranged γδ-TCR gene can be effectively generated. In particular, the method may be free of a step of treating the blood cells with an antibody before the step of stimulating blood cells with any one kind or a plurality of kinds of interleukins selected from IL-2, IL-15, and IL-23, and a bisphosphonate. In addition, iPS cells generated by the method of the present invention can be differentiated into desired cells by differentiation induction treatment. 1. A method of generating iPS cells , comprising the following steps 1) to 3):1) stimulating collected blood cells with any one kind or a plurality of kinds of interleukins selected from IL-2, IL-15, and IL-23, and a bisphosphonate;2) introducing at least four kinds of genes capable of expressing cell reprogramming factors into the blood cells through use of a Sendai virus vector; and3) culturing the cells having introduced therein the genes.2. The method of generating iPS cells according to claim 1 , wherein the cell reprogramming factors comprise OCT3/4 claim 1 , SOX2 claim 1 , KLF4 claim 1 , and c-MYC.3. The method of generating iPS cells according to claim 1 , wherein the interleukins comprise IL-2.4. The method of generating iPS cells according to claim 1 , wherein the bisphosphonate comprises one kind or a plurality of kinds selected from zoledronic acid claim 1 , pamidronic acid claim 1 , alendronic acid claim 1 , risedronic acid claim 1 , ibandronic acid claim 1 , incadronic acid claim 1 , etidronic acid claim 1 , minodronic acid claim 1 , salts thereof claim 1 ...

Подробнее
25-01-2018 дата публикации

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Номер: US20180023048A1
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. An animal protein-free cell culture medium , comprising at least one polyamine and at least one protein hydrolysate derived from the group consisting of plants and yeast , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to about 30 mg/L.2. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is selected from the group consisting of cadaverine claim 1 , putrescine claim 1 , spermidine claim 1 , spermine claim 1 , agmatine claim 1 , ornithine claim 1 , and a combination thereof.3. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is putrescine in a concentration ranging from about 0.5 to about 10 mg/L claim 1 , and the protein hydrolysate is soy hydrolysate in a concentration ranging from about 0.05% (w/v) to about 5% (w/v)4. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine originates from a source other than a protein hydrolysate.5. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to about 10 mg/L.6. The animal protein-free cell culture medium according to claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 2 to about 8 mg/L.7. The animal protein-free cell culture medium according to claim 1 , wherein the protein hydrolysate is present in ...

Подробнее
25-01-2018 дата публикации

MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA

Номер: US20180023052A1

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. 1. A method of treating or preventing retinal degeneration , comprising use of a cell selected from the group consisting of at least one of: RPE cells , RPE-like cells , RPE or RPE-like progenitors derived from mammalian embryonic stem cells.2. The method of claim 1 , wherein the condition of retinal degeneration is selected from the group consisting of at least one of: retinitis pigmentosa and macular degeneration.3. The method of claim 1 , further comprising transplantation of the cell by vitrectomy surgery into the subretinal space of the eye.4. The method of claim 3 , wherein the cells are transplanted in a suspension claim 3 , matrix claim 3 , or substrate.5. The method of claim 2 , wherein the retinitis pigmentosa is associated with an animal model.6. The method of claim 5 , where in the animal model is selected from the group consisting of: rd mouse claim 5 , RPE-65 knockout mouse claim 5 , tubby-like mouse claim 5 , RCS rat claim 5 , Abyssinian cat claim 5 , cone degeneration “cd” dog claim 5 , progressive rod-cone degeneration “prcd” dog claim 5 , early retinal degeneration “erd” dog claim 5 , rod-cone dysplasia 1 claim 5 , 2 & 3 “rcd1 claim 5 , rcd2 and rcd3” dogs claim 5 , photoreceptor dysplasia “pd” dog claim 5 , and Briard “RPE-65” dog.7. The method of claim 6 , wherein the outcome of the therapy in the animal model is evaluated using one or more of behavioral tests claim 6 , fluorescent angiography claim 6 , histology claim 6 , and functional testing such as measuring the ability of the cells to perform phagocytosis (photoreceptor fragments) claim 6 , vitamin A metabolism claim 6 , tight junctions conductivity claim 6 , or evaluation using electron microscopy.8. A method for the spontaneous differentiation ...

Подробнее
24-01-2019 дата публикации

Chondrocyte Precursors Derived From Human Embryonic Stem Cells

Номер: US20190024053A1
Автор: Thies R. Scott
Принадлежит:

This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy. 1. A cell population obtained by differentiating primate pluripotent stem (pPS) cells , in which at least 5% of the cells synthesize either Type II collagen or aggrecan from an endogenous gene:2. The cell population of claim 1 , in which less than 1% of the cells synthesize elastin claim 1 , Type I collagen claim 1 , Type X collagen claim 1 , or osteocalcin.3. The cell population of claim 1 , which causes closure of a 6 mm hole within 2 months in the animal model described by Koppel et al. claim 1 , Biomaterials 22:1407 claim 1 , 2001.4. A population of chondrocyte progenitors that proliferates in an in vitro culture claim 1 , obtained by differentiating primate pluripotent stem (pPS) cells claim 1 , and capable of forming progeny having the characteristics of the cells of .5. The cell population of claim 1 , comprising less than 1% undifferentiated pPS cells.6. The cell population of claim 1 , comprising cells that have been genetically altered to express telomerase reverse transcriptase (TERT) at an elevated level.7. Two cell populations claim 1 , comprising the differentiated cell population of claim 1 , and the undifferentiated pPS cell line from which it was obtained.8. A method for obtaining the cell population of claim 1 , comprising differentiating the pPS cells claim 1 , then culturing the differentiated cells with a mixture of chondrocyte differentiation factors.9. The method of claim ...

Подробнее
28-01-2021 дата публикации

BIOSYNTHETIC ACTIVITY OF THE ANAPLASMA PHAGOCYTOPHILUM AND EHRLICHIA CHAFFEENSIS PHAGOSOME IN A HOST CELL-FREE MEDIUM

Номер: US20210024879A1
Автор: Ganta Roman R.
Принадлежит:

Axenic media and methods for growing and/or are provided. In general, the axenic media includes intracellular phosphate buffer (IPB), a carbon source, FBS, a mixture of amino acids, and at least one further component selected from the group consisting of glucose 6-phosphate (G6P), ATP, DTT, GTP, UTP, CTP, and any combination thereof. 1. A composition comprising:a) intracellular phosphate buffer (IPB);b) a carbon source;c) FBS;d) a mixture of amino acids; ande) at least one further component selected from the group consisting of glucose 6-phosphate (G6P), ATP, DTT, GTP, UTP, CTP, and any combination thereof.2. The composition of further comprising phagosomes and/or mitochondria.3. (canceled)4. The composition of claim 1 , further comprising a bacterium from the family Anaplasmataceae.5Ehrlichia chaffeensis, Ehrlichia ewingii, Ehrlichia canis, Ehrlichia ruminantium, Ehrlichia muris euclarancis, Anaplasma marginale, Anaplasma phagocytophilum,. The composition of claim 4 , wherein the bacterium is selected from the group consisting of and any combination thereof.6. The composition of claim 1 , wherein said IPB comprises a mixture of at least one phosphate claim 1 , at least one gluconate claim 1 , and at least one chloride.7. The composition of claim 6 , wherein said at least one phosphate is selected from the group consisting of potassium phosphate claim 6 , sodium phosphate claim 6 , and any combination thereof claim 6 , and/or wherein said at least one chloride is selected from the group consisting of potassium chloride claim 6 , magnesium chloride claim 6 , and any combination thereof.8. The composition of claim 6 , wherein said at least one phosphate is included at a final concentration of at least 1 mM and/or wherein said gluconate is included at a final concentration between 70 mM and 150 mM claim 6 , and/or wherein said at least one chloride is included in the medium at a final concentration between 0.5 mM and 12 mM.9. The composition of claim 6 , wherein said ...

Подробнее
02-02-2017 дата публикации

DIFFERENTIATION OF STEM CELLS INTO THYROID TISSUE

Номер: US20170027994A1
Принадлежит:

Embodiments herein relate in vitro methods of stem cell differentiation into thyroid hormone producing cells and tissues, and methods of use of these cells. 1. An ex vivo or in vitro method for producing a thyroid follicular epithelial cell comprising: wherein the thyroid progenitor cell co-expresses a NK2 homeobox 1 (Nkx2-1) protein and a paired box 8 (Pax8) protein,', 'wherein the co-expression of Nkx2.1 and Pax8 are the products of endogenous genes within the cell, and the Nkx2.1 and Pax8 co-expressing thyroid progenitor cell does not comprise exogenously delivered nucleic acid sequences encoding for the co-expression of Nkx2.1 and Pax8 in the cell; and, 'a) culturing a thyroid progenitor cell in a differentiation medium under condition and time sufficient to further differentiate the thyroid progenitor cell along the thyroid lineage, wherein the differentiation medium comprising fibroblast growth factor 2 (basic) (FGF2),'} 'to produce a Nkx2-1+/Pax8+ co-expressing cell that also expresses early and mature thyroid markers: thyroglobulin (Tg+), thyroid stimulating hormone receptor (Tsh+), sodium iodine symporter (Nis+), and thyroid peroxidase (Tpo+).', 'b) then culturing the thyroid progenitor cell of step (a) in a maturation medium comprising dexamethasone and cAMP, or dexamethasone and thyroid stimulating hormone (TSH), or TSH, under condition and time sufficient'}2. The method according to claim 1 , wherein the thyroid progenitor cell is prepared by contacting an endodermal cell with a thyroid lineage culture medium to differentiate the endodermal cell into the thyroid lineage without exogenously delivered nucleic acid sequences resulting in the forced over-expression of the Nkx2-1 protein and the Pax8 protein in the endodermal cell claim 1 , thereby producing a Nkx2.1+ and Pax8+ thyroid progenitor cell claim 1 , wherein the thyroid lineage culture medium comprising:i) bone morphogenetic protein 4 (BMP4), andii) fibroblast growth factor 2 (basic) (FGF2),wherein ...

Подробнее
04-02-2016 дата публикации

THEOBROMINE COMPOSITIONS USEFUL FOR INCREASING FETAL WEIGHT GAIN AND ENHANCING BONE PROPERTIES

Номер: US20160030434A1
Принадлежит:

Compositions and methods for culturing cells with theobromine are provided, as well as cells derived thereby. Theobromine compositions for enhancing bone formation, increasing bone density, increasing interconnections of internal bone, increasing bone mass, treating cartilage and/or bone defects, increasing fetal birth weight, preventing tooth decay, remineralizing a tooth surface, treating dentine hypersensitivity, and application to a bone site to promote new bone growth at the site are also provided. 1. An isolated cell in a culture medium , said culture medium comprising theobromine , a salt or double salt of theobromine , or a co-crystal comprising theobromine.2. The isolated cell of claim 1 , wherein said isolated cell is a mammalian cell.3. The isolated cell of claim 1 , wherein said isolated cell is a stem cell.4. The stem cell of claim 3 , wherein said stem cell is a mesenchymal stem cell.5. The cell of claim 1 , wherein said theobromine claim 1 , salt or double salt of theobromine claim 1 , or co-crystal comprising theobromine is from 1 to 300 μM.6. A method of culturing a cell claim 1 , the method comprising:culturing said cell in a culture medium, wherein said culture medium comprises theobromine, a salt or double salt of theobromine, or a co-crystal comprising theobromine.7. The method of claim 6 , wherein said cell is a mammalian cell.8. The method of claim 6 , wherein said cell is a stem cell.9. The method of claim 8 , wherein said stem cell is a mesenchymal stem cell.10. The method of claim 6 , wherein said theobromine is from 1 to 300 μM.11. A culture medium comprising theobromine claim 6 , a salt or double salt of theobromine claim 6 , or a co-crystal comprising theobromine.12. The culture medium of claim 11 , wherein said theobromine claim 11 , salt or double salt of theobromine claim 11 , or co-crystal comprising theobromine is from 1 to 300 μM.13. The culture medium of claim 11 , wherein said theobromine claim 11 , salt or double salt of ...

Подробнее
29-01-2015 дата публикации

CULTURE MEDIUM FOR EUKARYOTIC CELLS

Номер: US20150031128A1
Принадлежит: FRIESLAND BRANDS B.V.

The invention pertains to the use of (i) one or more C-Calpha-hydroxy acids, salts of these acids, esters of these acids and combinations thereof; and (ii) one or more compounds selected from—the group of amino acid derivatives consisting of γ-glutamyl amino acids, pyroglutamyl amino acids, glutamate-containing or proline-containing dipeptides, oxo-aminoacids, homo-amino acids, N-acetyl amino-acids and glycyl-glycine; -phenolic acid derivatives; -linear C-Cor cyclic Csugar alcohols; -pyridinic acid derivatives; and -nucleobases and/or nucleotides chosen from uracil, adenine, adenosine 3′-monophosphate (3′-AMP) and adenosine 5′-monophosphate (AMP), as a growth-and production promoting ingredient, in culture media for culturing eukaryotic cells. The invention further pertains to culture media containing these components at levels of at least 0.001 mg/l. 1. A process of producing a culture medium for culturing eukaryotic cells comprising adding to conventional culture medium the following ingredients:{'sub': 2', '6, '(i) one or more C-Calpha-hydroxy acids, salts of these acids, esters of these acids and combinations thereof; and'} a) amino acid derivatives consisting of γ-glutamyl amino acids, pyroglutamyl amino acids, glutamate-containing or proline-containing dipeptides, oxo-aminoacids, homo-amino acids, N-acetyl amino-acids and glycyl-glycine;', 'b) phenolic acid derivatives;', {'sub': 2', '6', '6, 'c) linear C-Cor cyclic Csugar alcohols;'}, 'd) pyridinic acid derivatives; and', 'e) nucleobases and/or nucleotides chosen from uracil, adenine, adenosine 3′-monophosphate (3′-AMP) and adenosine 5′-monophosphate (AMP), or a combination of compounds selected from compound groups a), b), c), d) and e),, '(ii) one or more compounds selected from the following groups of compoundsas a growth-promoting and/or production-improving ingredient,such that the final concentration in the culture medium is at least 0.001 mg/l per individual compound listed under (i) and (ii), wherein ...

Подробнее
02-02-2017 дата публикации

CANINE AUTOLOGOUS IMMUNOTHERAPY USING DENDRITIC CELL INDUCED CANCER KILLING IMMUNOCYTES

Номер: US20170029775A1
Автор: Ichim Thomas, Koos David
Принадлежит:

Described are compositions of matter, protocols, and treatment means for induction of immune mediated killing in dogs suffering from cancer. The invention provides means of extracting peripheral blood from a canine patient, expanding immunocytes capable of killing cancer cells in vitro, and re-administering said immunocytes into a patient in need of therapy. In one embodiment, immunocytes expanded are T cells possessing tumor cytotoxic activity induced by stimulation of NKG2D. 1. A method of generating a canine immunocyte possessing cytotoxicity against cancer cells comprising: a) obtaining canine blood; b) isolating peripheral blood mononuclear cells from the canine blood; c) isolating monocytic cells from said canine blood; d) isolating CD355+ cells from the canine blood; e) inducing said monocytic cells to differentiate into dendritic cells; f) co-culturing said dendritic cells with said CD355+ expressing cells.2. The method of claim 1 , wherein said peripheral blood mononuclear cells are isolated from said canine blood by a density gradient.3. The method of claim 1 , wherein said peripheral blood mononuclear cells are isolated from said canine blood wherein said density gradient is percoll.4. The method of claim 1 , wherein said peripheral blood mononuclear cells are isolated from said canine blood wherein said density gradient is ficoll.5. The method of claim 1 , wherein said monocytic cells are collected by plastic adherence.6. The method of claim 1 , wherein said monocytic cells are collected by magnetic activated cell separation for CD14.7. The method of claim 1 , wherein said monocytic cells are collected by fluorescent activated cell separation for CD14.8. The method of claim 1 , wherein said cells expressing CD355 are collected by a means selected from a group comprising of: a) magnetic activated cell separation; b) fluorescent activated cell separation; and c) panning.9. The method of claim 1 , wherein said monocytic cells are differentiated into ...

Подробнее
04-02-2016 дата публикации

DIFFERENTIATION-INDUCING CULTURE MEDIUM ADDITIVE AND USE THEREOF

Номер: US20160032247A1
Принадлежит:

Provided is a differentiation-inducing culture medium additive for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell, a dental pulp cell, a periodontal ligament cell, a placenta, an amnion, and a fibroblast under a serum-free condition, and a use of the differentiation-inducing culture medium additive. The differentiation-inducing culture medium additive of the present invention for inducing differentiation of a stem cell under a serum-free condition at least contains at least one growth factor selected from the group consisting of EGF, FGF, and PDGF; dexamethasone; and β-glycerophosphate. The differentiation-inducing culture medium additive of the present invention does not require ascorbic acid 2-phosphate and ITS, which are normally essential for bone differentiation. Further, bone differentiation can be promoted by adding phospholipid. 1. A culture method for inducing bone differentiation of at least one type of cell selected from the group consisting of a stem cell , a dental pulp cell , a periodontal ligament cell , a placenta , an amnion , and a fibroblast under a serum-free condition ,the culture method comprising the step of:differentiating at least one type of cell selected from the group consisting of the stem cell, the dental pulp cell, the periodontal ligament cell, the placenta, the amnion, and the fibroblast in a culture medium,the culture medium comprising:at least one growth factor selected from the group consisting of EGF, FGF, and PDGF;dexamethasone;β-glycerophosphate; anda basal medium,the culture medium containing no serum.2. The culture method according to claim 1 , wherein the culture medium further contains at least one phospholipid.3. The culture method according to claim 2 , wherein the at least one phospholipid is selected from the group consisting of phosphatidic acid claim 2 , lysophosphatidic acid claim 2 , phosphatidylinositol claim 2 , phosphatidylserine claim 2 , ...

Подробнее
09-02-2017 дата публикации

METHOD AND CULTURE MEDIUM FOR PREPARING MAMMALIAN OVUM OR EMBRYO IN WHICH ZONA PELLUCIDA HAS BEEN THINNED OR ELIMINATED, AND METHOD FOR FERTILIZATION USING MAMMALIAN OVUM PREPARED BY SAME METHOD

Номер: US20170037433A1
Автор: Nakagata Naomi, Takeo Toru
Принадлежит:

Provided are a method for preparing a mammalian ovum or embryo in which zona pellucida has been thinned or eliminated, and a method for fertilization using the mammalian ovum prepared by the aforementioned method. The resulting mammalian ovum or embryo is capable of realizing an improved fertilization rate and development rate when used for in vitro fertilization, transplantation of a fertilized ovum, or for preparation of an embryo in the early stages of development used in the production of a genetically modified animal. 123.-. (canceled)24. A fertilizing method comprising:(a) pre-incubating mammal sperm with a sperm pre-incubation culture medium containing 0.1 mM or more and 20 mM or less methyl-β-cyclodextrin and 0.1 mM or more and 10 mM or less calcium for at least 10 min and collecting motile sperm,(b) treating an unfertilized mammal ovum with a medium containing reduced glutathione at a concentration of 0.25 mM or more and 10 mM or less in terms of SH equivalent for several minutes or more for thinning or elimination of the zona pellucida of the unfertilized ovum, and(c) adding the motile sperm pre-incubated in step (a) into a fertilization culture medium containing the unfertilized ovum previously treated with the reduced glutathione in step (b) in a dish and performing insemination.25. The fertilizing method according to claim 24 , wherein the unfertilized ovum is a mouse unfertilized ovum.26. The fertilizing method according to claim 25 , wherein the sperm to be used for fertilization are mouse frozen/thawed sperm and the pre-incubation in step (a) is conducted for 30-60 min.27. The fertilizing method according to claim 26 , wherein the concentration of methyl-β-cyclodextrin in step (a) is 0.5 mM or more and 3.0 mM or less and the concentration of the reduced glutathione in the medium in step (b) is 0.05 mM or more and 1.5 mM or less.28. The fertilizing method according to claim 27 , wherein the sperm pre-incubation medium in step (a) contains ...

Подробнее
12-02-2015 дата публикации

CELL LINE ADAPTED TO A PROTEIN-FREE AND LIPID-FREE MEDIUM, A METHOD FOR PRODUCING THE CELL LINE, AND A MEDIUM FOR THE CELL LINE

Номер: US20150044769A1
Автор: Sasaki Tetsuji

A cell of a cell line adapted to a protein-free and lipid-free medium, which is derived from CHO cells, can be stably used for production of recombinant proteins and can proliferate in a suspended state in a protein-free and lipid-free medium containing no exogenous growth factors. A method for adapting CHO cells by using a protein-free and lipid-free medium and a medium used for the method. 1. A cell of a cell line derived from Chinese Hamster Ovary (CHO) cells , the cell line being adapted to a protein-free and lipid-free medium , characterized in that the cell can proliferate in a suspended state in a protein-free and lipid-free medium comprising no exogenous growth factors.2. The cell as described in claim 1 , wherein the cell line has been deposited under Accession number NITE P-01641.3. A protein-free and lipid-free medium for culturing cells of an established cell line derived from CHO cells claim 1 , the cell line being adapted to a protein-free and lipid-free medium claim 1 , characterized by comprising putrescine claim 1 , thymidine claim 1 , hypoxanthine claim 1 , and monoethanolamine in a DMEM medium that has been modified so as to contain glucose in an amount of 3 to 5 times of the usual amount claim 1 , and by comprising no exogenous growth factors.4. The protein-free and lipid-free medium as described in claim 3 , which comprises 2000 to 5000 mg/L of glucose claim 3 , 0.001 to 2 mg/L of putrescine claim 3 , 0.01 to 1 mg/L of thymidine claim 3 , 0.1 to 10 mg/L of hypoxanthine claim 3 , and 0.1 to 5 mg/L of monoethanolamine.5. The protein-free and lipid-free medium as described in claim 3 , which further comprises 1 to 20 mg/L of insulin.6. A composition for producing the medium as described in claim 3 , which comprises claim 3 , in addition to the composition of the DMEM medium claim 3 , components of: 2000 to 5000 mg/L of glucose claim 3 , 0.001 to 2 mg/L of putrescine claim 3 , 0.01 to 1 mg/L of thymidine claim 3 , 0.1 to 10 mg/L of hypoxanthine ...

Подробнее
06-02-2020 дата публикации

CELL CULTURE MEDIA

Номер: US20200040301A1
Автор: Ince Tan
Принадлежит:

A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors. 121-. (canceled)22. A cell culture medium comprising:(a) adenosine triphosphate; (b) a carrier protein; (c) cholesterol, linoleic acid, and lipoic acid; (d) glutathione; (e) at least one nucleotide salvage pathway precursor base; (f) phosphoethanolamine; (g) selenium; (h) transferrin; (i) triiodothyronine; (j) all-trans-retinoic acid (ATRA) and vitamin C; (k) zinc, magnesium, and copper; (l) an agent that increases intracellular cAMP; (m) epidermal growth factor (EGF); (n) hydrocortisone; (o) insulin; and (p) charcoal-stripped fetal bovine serum; andwherein said cell culture medium is substantially free of estrogenic hormones and estrogenic ligands.23. The cell culture medium of claim 22 , wherein said culture medium is substantially free of vitamin D.24. The cell culture medium of claim 23 , wherein said culture medium is substantially free of androgenic hormones and androgenic ligands.25. The cell culture medium of claim 22 , wherein said culture medium is substantially free of androgenic hormones and androgenic ligands.26. A method of culturing breast cancer cells comprising claim 22 ,obtaining a sample of breast cancer cells from cancerous breast tissue,{'claim-ref': {'@idref': 'CLM-00022', 'claim 22'}, 'adding an amount of the cell culture medium of to the sample of breast cancer cells, and'}{'claim- ...

Подробнее
18-02-2016 дата публикации

CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOF

Номер: US20160045641A1
Принадлежит:

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct. 1. A cell sheet construct for neurovascular reconstruction , comprising:a vascular endothelial cell layer having vascular endothelial cells; anda neural stem cell layer having neural stem cells;wherein the vascular endothelial cell layer is physically in direct contact with the neural stem cell layer, the vascular endothelial cell layer differentiates into branching vasculatures, and the neural stem cell layer differentiates into neurons.2. The cell sheet construct of claim 1 , wherein the vascular endothelial cells are human cerebral microvascular endothelial cells.3. The cell sheet construct of claim 1 , wherein the neural stem cells are human cerebral neural stem cells.4. The cell sheet construct of claim 1 , wherein the vascular endothelial cell layer further comprises extracellular matrix claim 1 , and the extracellular matrix as well as the vascular endothelial cells are used as a carrier.5. The cell sheet construct of claim 4 , wherein the extracellular matrix comprises polypeptide claim 4 , collagen claim 4 , polysaccharide claim 4 , hyaluronic acid claim 4 , ...

Подробнее
18-02-2021 дата публикации

CULTURE SYSTEM FOR CHEMICALLY INDUCING GENERATION OF PLURIPOTENT STEM CELLS AND CHEMICAL REPROGRAMMING METHOD USING SAME

Номер: US20210047624A1
Принадлежит:

Disclosed herein is a culture system for chemical induction of pluripotent stem cells, comprising a basic culture medium and a composition for performing chemical induction of reprogramming process. The said composition comprises a thymine analogue, a cAMP activator, a TGF-β receptor inhibitor, a bone morphogenetic protein, a RA receptor activator, a GSK3 inhibitor and a basic fibroblast growth factor. And the said culture system is free of serum. By using the culture system as described herein, there is no need to frequently replate cells during culture, such that culturing process is simplified and loss of cells resulting from replating cells is reduced. As the culture system is free of serum, subsequent collection of pluripotent stem cells and molecular mechanism analysis are simplified, thereby facilitating establishment of no animal origin culture systems for induction of pluripotent stem cells. 1. A culture system for chemical induction of pluripotent stem cells , comprising a medium and a group consisting of: a thymine analogue , a cAMP activator , a TGF-β receptor inhibitor , a bone morphogenetic protein , a RA receptor activator , a GSK3 inhibitor and a basic fibroblast growth factor , wherein the said culture system is free of serum.2. The culture system of claim 1 , wherein claim 1 ,the thymine analogue has a concentration from 0.01 μM to 10 μM,the cAMP activator has a concentration from 0.01 μM to 10 μM,the TGF-β receptor inhibitor has a concentration from 0.01 μM to 5 μM, the bone morphogenetic protein has a concentration from 0.01 ng/ml to 10 ng/ml,the basic fibroblast growth factor has a concentration from 0.01 ng/ml to 10 ng/ml,the RA receptor activator has a concentration from 0.01 μM to 0.05 μM, and/or the GSK3 inhibitor has a concentration from 0.01 μM to 3 μM.3. The culture system of claim 2 , wherein claim 2 ,the thymine analogue is Brdu,the cAMP activator is FSK,the TGF-β receptor inhibitor is RepSox,the bone morphogenetic protein is BMP4,the ...

Подробнее
16-02-2017 дата публикации

NOCICEPTOR-LIKE CELLS DIFFERENTIATED FROM HUMAN NEURAL PROGENITORS AND USES THEREOF

Номер: US20170045499A1
Принадлежит:

Disclosed herein are methods of differentiating human neural progenitor cells to nociceptor-like cells. Also disclosed are methods of making an innervated skin-like construct using nociceptor-like cells differentiated from human neural progenitor cells. Also disclosed are engineered constructs for screening potentially therapeutic compounds that include a skin-like construct and nociceptor-like cells differentiated from human neural progenitor cells. Also disclosed is a method of screening potential therapies. 1. A method of differentiating human neural progenitor cells to nociceptor-like cells , comprising:a) exposing human neural progenitor cells to a first serum-free initiation medium for a first time period; andb) exposing the human neural progenitor cells to a second serum-free initiation medium for a second time period; andc) exposing the human neural progenitor cells to a serum-free differentiation medium during a third time period to cause at least a portion of the human neural progenitor cells to differentiate into nociceptor-like cells;wherein the nociceptor-like cells possess at least one nociceptor-like property.2. The method of claim 1 , wherein the first serum-free initiation medium comprises KSR base medium claim 1 , SB43152 claim 1 , and LDN-193189.3. The method of claim 2 , wherein the concentration of SB43152 in the first serum-free initiation medium is from 1-100 μM claim 2 , and wherein the concentration of LDN-193189 in the first-serum free initiation medium is from 10-1000 nM.4. The method of claim 3 , wherein the SB43152 concentration in the first-serum free initiation medium is about 10 μM claim 3 , and wherein the concentration of LDN-193189 in the first-serum free initiation medium is about 100 nM.5. The method of claim 1 , wherein the first time period is from 1-5 days.6. The method of claim 5 , wherein the first time period is about 2 days.7. The method of claim 1 , wherein the second serum-free initiation medium comprises SB43152 claim 1 ...

Подробнее
03-03-2022 дата публикации

METHODS RELATING TO PLURIPOTENT CELLS

Номер: US20220064593A1
Принадлежит:

The technology described herein relates to methods, assays, and compositions relating to causing a cell to assume a more pluripotent state, e.g. without introducing foreign genetic material. 1. Isolated cells expressing one or more markers of pluripotency formed by treating non-embryonic , non-transformed normal differentiated mammalian somatic cells with an effective amount of chemical stress comprising ATP to a concentration of between 20 μM and 200 mM , alone or in combination with a mechanical stress to increase the levels of stress inducible genes in an amount and for a time effective to increase the number of cells expressing one or more markers of pluripotency , wherein the cells are at a pH of between 3.0 and 6.8 ,without introduction of an exogenous gene, a transcript, a protein, a nuclear component or cytoplasm, or without cell fusion,wherein the one or more pluripotency markers are selected from the group consisting of Oct4, SSEA, Nanog and Sox2, thereby increasing the number of cells expressing the markers of pluripotency,wherein the cells are in tissue specific cell culture media.2. The cells of claim 1 , wherein the cell population is formed by the method further comprising exposure to mechanical stress disrupting pores resulting in loss of between about 40% and about 90% of the cytoplasm or the mitochondria from the cell claim 1 , in addition to chemical stress.3. The cells of claim 1 , wherein the mechanical disruption is achieved by trituration of the cells.4. The cells of claim 1 , wherein the stress is mechanical disruption of the pores of the cell membrane in the presence of ATP and exposure to a pH between 4.6 and 6.5. The cells of wherein the pH is between 5 and 5.7.6. The cells of wherein the ATP is in a concentration between one and 15 mM.7. The cells of wherein the cells are cultured in culture media for culturing embryonic neural stem cells.8. The cells of wherein the cells are cultured in culture media for culturing skin cells.9. The cells ...

Подробнее
03-03-2022 дата публикации

METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF

Номер: US20220064600A1
Принадлежит:

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation.

Подробнее
14-02-2019 дата публикации

PROCESS

Номер: US20190048375A1
Принадлежит:

The present invention relates to processes to make neosaxitoxin, and analogues and variants thereof, and intermediates in the production of neosaxitoxin in recombinant host cells. Neosaxitoxin and the analogues and variants thereof may be used in the production of pharmaceutical compositions. 1. A process for producing neosaxitoxin in a host cell , the process comprising the steps: (i) S-adenosylmethionine,', '(ii) arginine', '(iii) acetyl-CoA, malony-CoA or propionyl-CoA, and', '(iv) carbamoyl phosphate,, '(A) culturing a host cell which comprises nucleic acid molecules encoding a PPTase and encoding the Sxt polypeptides A, B, D, G, H, I, S, T, U, V, W and X in a culture medium in the presence of the substratesand wherein the host cell does not comprise nucleic acid molecules encoding the Sxt polypeptides C, F, J, K, L, M, P, Q, R and ORF24,under conditions which are suitable for the production of neosaxitoxin; and optionally(B) isolating and/or purifying neosaxitoxin from the host cells or from the culture medium.2. A process for producing neosaxitoxin or an analogue or variant thereof , the process comprising the steps: (i) S-adenosylmethionine,', '(ii) arginine', '(iii) acetyl-CoA, malony-CoA or propionyl-CoA, and', '(iv) carbamoyl phosphate,, '(A) contacting the substrateswith Sxt A, B, D, G, H, I, S, T, U, V, W and X polypeptides, in a reaction medium, and optionally(B) isolating and/or purifying neosaxitoxin or an analogue or variant thereof from the reaction medium.3. A process as claimed in claim 2 , wherein the reaction medium additionally comprises a PPTase.4. A process for producing neosaxitoxin or an analogue or variant thereof in a host cell claim 2 , the process comprising the steps: (i) S-adenosylmethionine,', '(ii) arginine', '(iii) acetyl-CoA, malony-CoA or propionyl-CoA, and', '(iv) carbamoyl phosphate,, '(A) culturing a host cell which comprises nucleic acid molecules encoding the Sxt polypeptides A, B, D, G, H, I, S, T, U, V, W and X in a ...

Подробнее
25-02-2021 дата публикации

METHOD FOR INCREASING DENDRITIC CELL MIGRATION ABILITY, AND USE THEREOF

Номер: US20210054335A1

A method for increasing dendritic cell migration ability, and a use thereof are disclosed. A method according to one aspect can increase the migration ability of mature dendritic cells and increase the induction, by dendritic cells, of inflammatory cytokine production, T lymphocyte proliferation and T lymphocyte polarization, and thus can be used for the prevention or treatment of immune-related diseases. 1. A method of preparing mature dendritic cells having increased migration ability , the method comprising contacting immature dendritic cells with autotaxin.2. The method of claim 1 , wherein the immature dendritic cells are immature dendritic cells claim 1 , semi-mature dendritic cells claim 1 , or a combination thereof.3. The method of claim 1 , wherein the immature dendritic cells are obtained by culturing bone marrow cells from which red blood cells were removed.4. The method of claim 1 , wherein the contacting is performed in an RPMI medium.5. The method of claim 4 , wherein the medium comprises fetal bovine serum (FBS) claim 4 , granulocyte-macrophage colony-stimulating factor (GM-CSF) claim 4 , interleukin (IL) claim 4 , and mercaptoethanol.6. The method of claim 1 , further comprising contacting the immature dendritic cells with lipopolysaccharide (LPS) claim 1 , keyhole limpet hemocyanin (KLH) claim 1 , or a combination thereof.7. The method of claim 1 , wherein the method increases induction of inflammatory cytokine production claim 1 , induction of T lymphocyte proliferation claim 1 , or induction of T lymphocyte polarization of dendritic cells.8. A pharmaceutical composition for preventing or treating a disease selected from the group consisting of autoimmune diseases claim 1 , cancers claim 1 , infectious diseases claim 1 , and inflammatory diseases claim 1 , the pharmaceutical composition comprising mature dendritic cells having increased migration ability claim 1 , the mature dendritic cells being prepared by the method of .9. Mature dendritic cells ...

Подробнее
22-02-2018 дата публикации

Chelated iron-containing culture medium for neural stem cells

Номер: US20180051250A1
Принадлежит: Ajinomoto Co Inc

Culture media, which contain chelated iron, promote cell proliferation of neural stem cells and/or neural progenitor cells while maintaining undifferentiated state and multipotency.

Подробнее
15-05-2014 дата публикации

Chondrocyte Precursors Derived From Human Embryonic Stem Cells

Номер: US20140134721A1
Автор: R. Scott Thies
Принадлежит: Asterias Biotherapeutics Inc

This invention provides a system for obtaining cells of the chondrocyte lineage by differentiating primate pluripotent stem cells. The process involves culturing the cells as a micromass or other aggregate form in a cocktail of differentiation agents that facilitates outgrowth of the desired cell type. Progeny are capable of synthesizing Type II collagen or aggrecan, or other products that are characteristic of the chondrocyte lineage. Chondrocytes and chondrocyte precursor cells obtained according to this disclosure are suitable for use in both research and clinical therapy.

Подробнее
21-02-2019 дата публикации

METHOD OF DIFFERENTIATING HUMAN PLURIPOTENT STEM CELLS TO PODOCYTES

Номер: US20190055520A1
Принадлежит:

The present invention provides methods and kits for differentiating podocytes from pluripotent stem cells and from other cell types. 1. A method of producing nephron progenitor cells , the method comprising:{'sup': +', '+', '+', '+, 'a) culturing a Brachyury primitive streak cell population in a nephron progenitor differentiation medium free of exogenous Wnt/β-catenin activating agent, bone morphogenetic proteins (BMPs), Activin, retinoic acid (RA), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) for a time sufficient to differentiate a portion of the cultured cells into PAX2 WT1 SIX2 nephron progenitor cells.'}2. The method of claim 1 , wherein at least 75% of the differentiated cells are PAX2 WT1 SIX2 nephron progenitor cells.3. The method of claim 2 , wherein at least 90% of the differentiated cells are PAX2 WT1 SIX2nephron progenitor cells.4. The method of claim 3 , wherein at least 95% of the differentiated cells are PAX2 WT1 SIX2nephron progenitor cells.5. The method of claim 1 , wherein the sufficient time is at least 4 days.6. A method of producing immature podocytes claim 1 , the method comprising:{'sup': +', '+', '+', '+, 'a) culturing a Brachyury primitive streak cell population in a nephron progenitor differentiation medium free of exogenous Wnt/β-catenin activating agent, bone morphogenetic proteins (BMPs), Activin, retinoic acid (RA), vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) for a time sufficient to differentiate a portion of the cultured cells into PAX2 WT1 SIX2 nephron progenitor cells; and'}{'sup': +', '+', '+', '+', '+', '+', '−, '(b) culturing the PAX2 WT1 SIX2 nephron progenitor cells in podocyte differentiation medium free of exogenous Wnt/β-catenin signaling activating agent, BMPs, Activin, RA, VEGF and FGF for a time sufficient to differentiate the PAX2 WT1 SIX2 nephron progenitor cells into SIX2 immature podocyte cells that express two or more markers selected from the group ...

Подробнее
02-03-2017 дата публикации

CELL CULTURE MEDIA

Номер: US20170058259A1
Автор: Ince Tan A.
Принадлежит:

A cell culture medium comprising adenosine triphosphate; a carrier protein; cholesterol, linoleic acid, and lipoic acid; glutathione; at least one nucleotide salvage pathway precursor base; phosphoethanolamine; selenium; transferrin; triiodothyronine; all-trans-retinoic acid (ATRA) and vitamin C; zinc, magnesium, and copper; an agent that increases intracellular cAMP; epidermal growth factor (EGF); hydrocortisone; insulin; and charcoal stripped fetal bovine serum, wherein said cell culture medium is substantially free, if not entirely free, of vitamin D, androgenic hormones, androgenic ligands, estrogenic hormones, estrogenic ligands, and/or androgenic receptors. 1. A cell culture medium comprising:(a) adenosine triphosphate;(b) a carrier protein;(c) cholesterol, linoleic acid, and lipoic acid;(d) glutathione;(e) at least one nucleotide salvage pathway precursor base,(f) phosphoethanolamine;(g) selenium;(h) transferrin;(i) triiodothyronine;(j) all-trans-retinoic acid (ATRA) and vitamin C;(k) zinc, magnesium, and copper;(l) an agent that increases intracellular cAMP;(m) epidermal growth factor (EGF);(n) hydrocortisone;(o) insulin; and(p) charcoal stripped fetal bovine serum;wherein said cell culture medium is substantially free of vitamin D.2. The cell culture medium as recited in wherein said medium is substantially free of any variety of vitamin D and vitamin D precursors claim 1 , derivatives claim 1 , or intermediates.3. The cell culture medium as recited in wherein said medium is substantially free of vitamin D2 claim 2 , vitamin D3 claim 2 , calciferol claim 2 , calcitriol claim 2 , drisdol claim 2 , 7-dehydrocholesterol claim 2 , cholecalciferol claim 2 , 25-hydroxyvitamin D3 claim 2 , and 1 claim 2 ,25-dihydroxyvitamin D3.4. The cell culture medium of configured to support proliferation of breast cancer cells for at least about 15 population doublings.5. A cell culture medium comprising:(a) adenosine triphosphate;(b) a carrier protein;(c) cholesterol, ...

Подробнее
20-02-2020 дата публикации

OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION

Номер: US20200057052A1
Принадлежит:

The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome. 1. An in vivo or in vitro method for inducing UBE3A expression in a target cell where expression of paternal UBE3A is suppressed, said method comprising administering an oligonucleotide consisting of TTAcActtaattatactTCC (SEQ ID NO: 626), wherein capital letters represent beta-D-oxy LNA nucleosides, lowercase letters represent DNA nucleosides, all LNA C are 5-methyl cytosine, and all internucleoside linkages are phosphorothioate internucleoside linkages, in an effective amount to said cell. This application is a continuation and claims priority to application Ser. No. 16/388,714, filed Apr. 18, 2019, which is a continuation and claims priority to application Ser. No. 15/351,113, filed Nov. 14, 2016, which is a continuation and claims priority to PCT/EP2016/077383, filed Nov. 11, 2016, which claims priority to EP15194367.7, filed Nov. 12, 2015 and EP161895024, filed Sep. 19, 2016. The contents of which are hereby incorporated by reference.The present invention relates to oligonucleotides (oligomers) that are complementary to and hybridize to SNHG14 downstream of SNORD109B, leading to induction of paternal expression of Ubiquitin-protein ligase E3A (UBE3A) in an animal or human. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.Angelman syndrome is neuro-genetic disorder caused by deletion or inactivation of the UBE3A genes on the maternally inherited chromosome 15q11.2. The paternal copy of the UBE3A gene is subject to genomic imprinting and silencing in neurons by ...

Подробнее
17-03-2022 дата публикации

NON-NATURALLY OCCURRING THERMOGENIC ADIPOCYTES, METHODS OF MAKING, AND METHODS OF USE THEREOF

Номер: US20220079993A1
Принадлежит:

Non-naturally occurring thermogenic adipocytes are provided. The cells have a distinctive molecular signature, and can be distinguished from predecessor cells such as adipose-derived stem cells as well as other naturally occurring and induced thermogenic cells. Differentiation media that can induce differentiation of ADSC and white adipocytes into thermogenic adipocytes is also provided. Methods of making thermogenic adipocytes, thermogenic adipocytes made according the disclosed methods as well as conditioned media made according a method of incubating the cells in a tissue culture media are also provided. Compositions including thermogenic adipocytes, conditioned media, secreted factor(s), active agents that increase the number or activity of thermogenic adipocytes, or a combination thereof are also disclosed and can be used to treat a variety of diseases and conditions, particularly obesity and metabolic disorders. 1. A thermogenic adipocyte comprising(i) increased uncoupling protein 1 (UCP1) expression, increased Type II iodothyronine deiodinase (DIO2) expression, or a combination thereof relative to naturally-occurring Adipose-derived stem cells (ADSC), white adipocytes (WAT), or a combination thereof; and(ii) reduced Intercellular Adhesion Molecule 1 (ICAM1) expression, increased matrix metalloproteinase-3 (MMP3) expression, or a combination thereof relative to naturally-occurring brown adipocytes (BAT), beige cells, or a combination thereof.2. The thermogenic adipocyte of comprising increased UCP1 and DIO2 expression.3. The thermogenic adipocyte of comprising reduced ICAM1 and increased MMP3 expression relative to naturally-occurring brown adipocytes (BAT) claim 1 , beige cells claim 1 , or a combination thereof.4. The thermogenic adipocyte of claim 1 , wherein the expression comprises mRNA expression claim 1 , protein expression claim 1 , or the combination thereof.5. The thermogenic adipocyte of claim 1 , wherein UCP1 expression claim 1 , DIO2 expression ...

Подробнее
22-05-2014 дата публикации

Thermoplastic resin composition for impact absorbing member and method for producing same

Номер: US20140142219A1
Принадлежит: TORAY INDUSTRIES INC

A thermoplastic resin composition includes 1 to 200 parts by weight of an inorganic filler (C) blended with 50 to 80 parts by weight of a thermoplastic resin (A) and 20 to 50 parts by weight of a rubbery polymer having a reactive functional group (B) which together account for 100 parts by weight; wherein the thermoplastic resin (A) and the rubbery polymer having a reactive functional group (B) form a continuous phase and a dispersed phase, respectively, while the inorganic filler (C) is dispersed in the continuous phase and/or the dispersed phase; and the dispersed phase of the rubbery polymer contains fine particles with a diameter of 1 to 100 nm of a compound resulting from a reaction between the thermoplastic resin (A) and the rubbery polymer; and an area occupied by the fine particles account for 10% or more of the dispersed phase.

Подробнее
10-03-2016 дата публикации

OLIGOPEPTIDE-FREE CELL CULTURE MEDIA

Номер: US20160068587A1
Принадлежит:

The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine. The invention also relates to methods for expressing at least one protein in a medium comprising at least 0.5 mg/L of a polyamine and to methods for producing at least one virus in a medium comprising at least 0.5 mg/L of a polyamine. 1. A method for expressing a coagulation factor VIII protein , comprising the steps of:(a) providing a culture of CHO cells;(b) introducing at least one nucleic acid sequence comprising a sequence coding for the coagulation factor VIII protein into the cells;(c) selecting the cells carrying the nucleic acid sequence; and(d) expressing the coagulation factor VIII protein in an oligopeptide-free chemically defined medium comprising DMEM:HAM's F12 (1:1) basal medium, putrescine at a concentration of at least 1 mg/L, and Fe(II) and Cu(II) at a level greater than the amount in basal DMEM:HAM's F12 (1:1), wherein the cells are cultivated by chemostat cultivation.2. The method of claim 1 , wherein the putrescine is present in the culture medium at a concentration ranging from 1 to 20 mg/L.3. The method of claim 1 , wherein the chemically defined medium is supplemented with L-glutamine claim 1 , ascorbic acid claim 1 , ethanolamine claim 1 , sodium selenite claim 1 , and a non-ionic surfactant. This application is a continuation of U.S. patent application Ser. No. 13/035,696 filed Feb. 25, 2011, which is a continuation of U.S. patent application Ser. No. 11/649,694 filed Jan. 3, 2007, which claims benefit of U.S. provisional application Ser. No. 60/756,419 filed Jan. 4, 2006, which applications are herein incorporated by reference.The present invention relates to oligopeptide-free cell culture media comprising at least 0.5 mg/L of a polyamine and to methods for cultivating cells in said oligopeptide-free ...

Подробнее
10-03-2016 дата публикации

METHOD FOR CULTURING SKELETAL MUSCLE FOR TISSUE ENGINEERING

Номер: US20160068812A1
Принадлежит:

The invention provides a nutrient medium composition and associated methods for lengthening the useful life of a culture of muscle cells. Disclosed is a method of culturing mammalian muscle cells, including preparing one or more carriers coated with a covalently bonded monolayer of trimethoxy-silylpropyl-diethylenetriamine (DETA); verifying DETA monolayer formation by one or more associated optical parameters; suspending isolated fetal rat skeletal muscle cells in serum-free medium according to medium composition 1; plating the suspended cells onto the prepared carriers at a predetermined density; leaving the carriers undisturbed for cells to adhere to the DETA monolayer; covering the carriers with a mixture of medium 1 and medium 2; and incubating. A cell nutrient medium composition includes Neurobasal, an antibiotic-antimycotic composition, cholesterol, human TNF-alpha, PDGF BB, vasoactive intestinal peptides, insulin-like growth factor 1, NAP, r-Apolipoprotein E2, purified mouse Laminin, beta amyloid, human tenascin-C protein, rr-Sonic hedgehog Shh N-terminal, and rr-Agrin C terminal. 122-. (canceled)23. A method of maintaining a muscle cell culture , the method comprising:maintaining the muscle cell culture in a serum-free medium comprising NBActiv4.24. The method of claim 23 , wherein the muscle cell culture is maintained in a serum-free medium comprising NBActiv4 for at least 30 days.25. The method of claim 24 , wherein the muscle cell culture is maintained in a serum-free medium comprising NBActiv4 for at least 50 days.26. The method of claim 23 , further comprising plating the muscle cell culture onto a non-biological growth substrate prior to maintaining the muscle cell culture in a serum-free medium comprising NBActiv4.27. The method of claim 26 , wherein the non-biological growth substrate comprises a silane molecule.28. The method of claim 27 , wherein the non-biological growth substrate is DETA.29. The method of claim 23 , further comprising plating the ...

Подробнее
10-03-2016 дата публикации

DIFFERENTIATION OF ADIPOSE STROMAL CELLS INTO OSTEOBLASTS AND USES THEREOF

Номер: US20160068813A1
Автор: Halvorsen Yuan-Di C.
Принадлежит:

The invention provides methods and compositions for differentiating stromal cells from adipose tissue into cells having osteoblastic properties, and methods for improving a subject's bone structure. The methods comprise culturing stromal cells from adipose tissue in β-glycerophosphate and ascorbic acid and/or ascorbate-2-phosphate for a time sufficient to allow differentiation of said cells into osteoblasts. Such methods and compositions are useful in the production of osteoblasts for autologous transplantation into bone at a surgical site or injury. The compositions comprise adipose stromal cells, a medium capable of supporting the growth of fibroblasts and amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2-phosphate sufficient to induce the differentiation of said stromal cells into osteoblasts. 1. A method of differentiating adipose stromal cells into osteoblasts , comprising: culturing said cells in a composition comprising a medium capable of supporting the growth of fibroblasts and differentiation inducing amounts of β-glycerophosphate and ascorbic acid and/or ascorbic-2-phosphate.2. The method of claim 1 , wherein said amounts are about 2-20 mM β-glycerophosphate and about 20-75 μM ascorbic acid and/or ascorbic-2-phosphate.3. The method of wherein said amounts are about 5-15 mM β-glycerophosphate and about 40-60 μM ascorbic acid and/or ascorbic-2-phosphate.4. The method of claim 3 , wherein said amounts are about 10 mM β-glycerophosphate and about 50 μM ascorbic acid and/or ascorbic-2-phosphate.5. The method of claim 1 , wherein said medium is selected from the group consisting of: DMEM claim 1 , aMEM and BME.6. The method of claim 1 , wherein said medium further comprises about 5-20% fetal calf serum.7. The method of claim 1 , wherein said medium further comprises one or more bone morphogenetic proteins.8. The method of wherein said cells are mammalian.9. The method of wherein said cells are human.10. A method of improving a subject's bone ...

Подробнее
10-03-2016 дата публикации

Methods of cell culture

Номер: US20160068881A1
Автор: Holly Prentice
Принадлежит: Momenta Pharmaceuticals Inc

Polypeptide preparations having target levels of glycans, and methods of producing such polypeptide preparations using putrescine, are described.

Подробнее
09-03-2017 дата публикации

SYNTHETIC CORNEA FROM RETINAL STEM CELLS

Номер: US20170065642A1
Принадлежит:

Methods of producing synthetic corneas are disclosed which are differentiated from retinal stem cells (rSC) derived from parthenogenetically activated human oocytes, including that such synthetic corneas are produced in the absence of a 3-D scaffold. Isolated synthetic corneas, produced by the disclosed methods, are also described. 1. A method of producing a synthetic cornea comprising:{'sub': 2', '2, 'a) parthenogenetically activating a human oocyte, wherein activating comprises: i) contacting the oocyte with an ionophore at high Otension and ii) contacting the oocyte with a serine-threonine kinase inhibitor at low Otension;'}{'sub': '2', 'b) cultivating the activated oocyte of step (a) at low Otension until blastocyst formation;'}{'sub': '2', 'c) transferring the blastocyst to a layer of feeder cells, and culturing the transferred blastocyst under high Otension;'}d) mechanically isolating an inner cell mass (ICM) from trophectoderm of the blastocyst of step (c);{'sub': '2', 'e) culturing the cells of the ICM of step (d) on a layer of human feeder cells under high Otension, wherein retinal stem cells are identified in the culture by human embryonic stem cell markers (hES) and neuron specific markers, and wherein the identified retinal stem cells are subsequently isolated;'}f) culturing the isolated stem cells of step (e) in media comprising serum replacement (M/SR), plasmonate, and at least one mitogen that activates the gp130/STAT pathway and/or the MAP kinase pathway on a fibroblast feeder layer treated with a DNA synthesis inhibitor;g) culturing the mitogen treated cells of step (f) in M/SR comprising plasmonate (M/SRP), without added mitogen, to near confluence, wherein ½ volume of the M/SRP is replaced with M/SR periodically until the near confluent cells develop pigmentation and a domed appearance; andh) transferring the pigmented cells of step (g) in M/SR to a gelatin coated substrate, wherein ½ volume of the M/SR is replaced with M/SR periodically until a ...

Подробнее
27-02-2020 дата публикации

Use of n-butylidenephthalide in dopaminergic progenitor cell transplantation

Номер: US20200063098A1

Uses of n-butylidenephthalide (BP) in dopaminergic progenitor cell transplantation are provided, wherein the uses include using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation, and using a combination of BP and BP-treated dopaminergic progenitor cells in dopaminergic progenitor cell transplantation. The uses especially relate to using BP to enhance the therapeutic effect of dopaminergic progenitor cell transplantation on Parkinson's disease.

Подробнее
11-03-2021 дата публикации

Cell Culture Medium for Eukaryotic Cells

Номер: US20210071135A1
Принадлежит:

Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells. 1. A cell culture medium for eukaryotic cells expressing Aflibercept , comprising:a basal medium or a feed medium; and5-methylthioadenosine or nicotinamide.2. The cell culture medium of claim 1 , wherein a concentration of 5-methylthioadenosine in the cell culture medium is at least about 10 nM.3. The cell culture medium of claim 1 , wherein a concentration of the nicotinamide in the cell culture medium is at least about 50 nM.4. The cell culture medium of further comprising one or more acids selected from lactic acid claim 1 , phenyl lactic acid claim 1 , indolelactic acid claim 1 , succinic acid claim 1 , alpha-hydroxyisovaleric acid claim 1 , alpha-hydroxyisocaproic acid claim 1 , 2-(4-hydroxyphenyl)lactic acid claim 1 , or 2-hydroxy-3-methylvaleric acid claim 1 , salts of these acids claim 1 , esters of these acids and combinations thereof.5. The cell culture medium of claim 2 , wherein a titer of the Aflibercept produced in the cell culture medium is at least about 2% greater than another cell culture medium that does not have at least about 10 nM 5-methylthioadenosine.6. The cell culture medium of claim 3 , wherein a titer of the Aflibercept produced in the cell culture medium is at least about 2% greater than another cell culture medium that does not have at least about 50 nM nicotinamide.7. The cell culture medium of claim 1 , wherein the 5-methylthioadenosine or the nicotinamide can be in the form of its salts or esters.8. The cell culture medium of claim 1 , wherein pH of the medium is maintained in the range of about 6.5 to about 8.9. The cell culture medium of claim 1 , wherein the medium does not have a protein derived from an animal.10. The cell culture medium of claim 1 , wherein the medium is a serum-free medium.11. The cell culture medium of claim 1 , wherein the medium is a chemically-defined medium.1231.-. (canceled)32. A ...

Подробнее
12-03-2015 дата публикации

DIFFERENTIATED HUMAN LIVER CELL CULTURES AND THEIR USE IN BIOARTIFICIAL LIVER SYSTEMS

Номер: US20150073389A1

Human hepatocyte cell cultures and their use in bioreactors and bioartificial liver (BAL) systems are provided. The cells have constitutive liver-specific metabolic activity resembling that of freshly isolated human hepatocytes. The hepatocyte cells and BAL systems can be used to treat patients suffering from acute liver failure, end-stage liver disease, or acute-on-chronic liver disease. 1. A cell culture comprising differentiated cells from a human hepatocyte cell line in a suitable culture medium , wherein said differentiated cells have constitutive liver-specific metabolic activity , the cell culture being obtained by a process comprising:selecting a human hepatocyte cell line;a phase of cell proliferation comprising culturing cells of said human hepatocyte cell line in a suitable culture medium, preferably comprising serum, hormones, growth-factors and antibiotics;loading viable cells to an amount of at least 5% of normal liver mass in a bioreactor comprising a three dimensional support matrix, and allowing the cells to attach to said matrix;an expansion or proliferation phase comprising culturing the cells loaded in the bioreactor in a suitable culture medium, preferably comprising serum, hormones, growth-factors and antibiotics, to achieve at least one cell population doubling; anda phase of cell differentiation comprising culturing the cells in a culture medium comprising serum, hormones, growth factors and antibiotics.2. The cell culture according to claim 1 , wherein the cell differentiation phase lasts at least 7 days.3. The cell culture according to claim 1 , wherein the three dimensional support matrix comprises a porous sheet or mat claim 1 , a fiber network matrix claim 1 , an open-pore foam claim 1 , or a semi-solid material.4. The cell culture according to claim 1 , wherein said human hepatocyte cell line is HepaRG claim 1 , deposited at the Collection Nationale de Cultures de Microorganismes claim 1 , Institut Pasteur claim 1 , Accession No. 1-2652 ...

Подробнее
07-03-2019 дата публикации

COMPOSITIONS AND METHODS FOR CULTURING CELLS FROM NORMAL HUMAN TUBO-OVARIAN EPITHELIUM AND HUMAN TUBO-OVARIAN TUMORS

Номер: US20190071634A1
Автор: Ince Tan A.
Принадлежит:

Described herein are cell culture media, kits and methods for preparing cell culture media, and methods for culturing cells, for example, cells of the female reproductive tract, and tumor cells. 1. A cell culture medium , or a kit for preparing a cell culture medium , comprising:(a) adenosine triphosphate;(b) a carrier protein;(c) cholesterol, linoleic acid, and lipoic acid;(d) glutathione;(e) a nucleotide salvage pathway precursor base selected from hypoxanthine, xanthine, adenine, guanine and thymidine;(f) phosphoethanolamine;(g) selenium;(h) transferrin;(i) triiodothyronine;(j) vitamin A, vitamin C, and vitamin D;(k) Zn, Mg, and Cu;(l) an agent that increases intracellular cAMP;(m) epidermal growth factor (EGF);(n) hydrocortisone;(o) insulin; and(p) serum.2. The cell culture medium of claim 1 , further comprising one or more of:(a) adenosine monophosphate;(b) vitamin E; or(c) at least one of vitamin K3, niacin, or niacinamide.3. (canceled)4. The cell culture medium of claim 1 , wherein the carrier protein is albumin.57-. (canceled)8. The cell culture medium of claim 1 , wherein the agent that increases intracellular cAMP is cholera toxin.924-. (canceled)25. The cell culture medium of claim 1 , further comprising an estrogen.2627-. (canceled)28. The cell culture medium of claim 25 , wherein the estrogen is 17-beta-estradiol.29. The cell culture medium of claim 1 , wherein the medium is substantially free of estrogen.3036-. (canceled)37. The cell culture medium of claim 1 , wherein the medium supports proliferation of ovarian tumor cells for at least about 15 population doublings (PD) in vitro.38. The cell culture medium of claim 1 , wherein the medium supports proliferation of ovarian cells and/or fallopian tube cells for at least about 15 population doublings (PD) in vitro.39. A kit for preparing the cell culture medium of claim 1 , comprising a first one or more containers comprising components (a)-(k) and a second one or more containers comprising components (l ...

Подробнее
07-03-2019 дата публикации

EFFICIENT DIFFERENTIATION OF HUMAN STEM CELLS TO DEFINITIVE ENDODERM

Номер: US20190071645A1
Автор: Mora Sergio
Принадлежит:

The present disclosure provides a medium for cells, such as human stem cells including human induced pluripotent stem cells (iPScs) which medium enhances the formation of definitive endoderm (DE) which in turn can be subsequently directed and differentiated into mature cell types, e.g., pancreas insulin producing cells. 1. A cell medium composition , comprising:a) one or more base tissue culture media;an amount of glutamine or an analog thereof;an amount of one or more lipids;an amount of one or more non-essential amino acids;an amount of one or more thiols;an amount of one or more of insulin, transferrin or selenium; andan amount of polyvinylalcohol; orb) one or more base tissue culture media;an amount of glutamine or an analog thereof;an amount of one or more non-essential amino acids; and optionally an amount of an inhibitor of glycogen synthase kinase 3 or an amount of an inhibitor of AMP activated protein kinase; orc) one or more base tissue culture media;an amount of glutamine or an analog thereof;an amount of selenium; and optionally an amount of an inhibitor of glycogen synthase kinase 3 or an amount of an inhibitor of AMP activated protein kinase.2. The composition of further comprising an amount of Activin claim 1 , comprising an amount of an activator of WNT signaling or an inhibitor of glycogen synthase kinase 3.3. The composition of wherein the amount of Activin is about 50 ng/mL to about 150 ng/mL.4. The composition of wherein the activator of WNT signaling or the inhibitor of glycogen synthase kinase 3 comprises CHIR99021.5. The composition of wherein the amount of CHIR99021 is about 1 μM to about 3 μM.6. The composition of wherein the amount of glutamine or the analog thereof comprises about 0.1% vol/vol to about 5% vol/vol.7. The composition of wherein the amount of the one or more lipids comprises about 0.1% vol/vol to about 5% vol/vol.8. The composition of wherein the thiol comprises monothioglycerol.9. The composition of wherein the amount of the ...

Подробнее
24-03-2022 дата публикации

METHOD OF PRODUCING ENTERIC NEURONS AND USES THEREOF

Номер: US20220090010A1
Автор: Fattahi Faranak
Принадлежит:

The present disclosure relates generally to methods and systems of producing enteric neurons from pluripotent stem cells under fully defined conditions. The enteric neural crest cells and enteric neurons produced by the disclosed methods find applications as models of the enteric nervous system, tools for high-throughput screening of potential therapeutics for treatment of enteric neuropathies, and in regenerative medicine. 1. A method of culturing pluripotent stem cells comprising:(a) diluting pluripotent stem cells with a culture medium to obtain a pluripotent stem cell mixture;(b) centrifuging the pluripotent stem cell mixture to obtain a pellet and a supernatant;(c) removing the supernatant from the pellet;(d) adding culture medium to the pellet and resuspending the pluripotent stem cells in the culture medium to obtain resuspended pluripotent stem cells;(e) plating the resuspended pluripotent stem cells on a hydrogel disposed within a culture vessel to obtain plated pluripotent stem cells; and(f) incubating the plated pluripotent stem cells to a confluency of about 80%.2. The method of claim 1 , wherein claim 1 , in step (a) or (d) claim 1 , the culture medium is removed and replaced with fresh culture medium about every 2 days.3. (canceled)4. The method of claim 1 , wherein the pluripotent stem cells are human pluripotent stem cells.5. The method of claim 1 , wherein the pluripotent stem cells are selected from the group consisting of human ES cell line H9 (WA-09) claim 1 , human ES cell line UCSF4 claim 1 , human iPS cell line WTC11 claim 1 , and combinations thereof.6. The method of claim 1 , wherein the hydrogel comprises a solubilized basement membrane preparation extracted from Engelbreth-Holm-Swarm mouse sarcoma claim 1 , the solubilized basement membrane preparation comprising a laminin claim 1 , a collagen IV claim 1 , a heparin sulfate proteoglycan claim 1 , and entactin/nidogen.7. The method of claim 1 , wherein the hydrogel comprises vitronectin.8. ...

Подробнее
16-03-2017 дата публикации

MEDIUM CONTAINING URIDINE AND N-ACETYL-D-MANNOSAMINE

Номер: US20170073633A1
Принадлежит: JCR PHARMACEUTICALS CO., LTD.

Provided are a novel medium for expressing glycoproteins by culturing cells and a method for producing glycoproteins by culturing cells in said medium. Further provided are a medium comprising uridine and N-acethyl-D-mannosamine for the use of expression of a glycoprotein by culturing cells and a method for producing glycoproteins by culturing cells in said medium. 1. A medium , comprising:uridine at a concentration of 0.5 to 10 mM; andN-acethyl-D-mannosamine at a concentration of 1 to 15 mM.2. The medium according to claim 1 , wherein the concentration of uridine is 1 to 8 mM claim 1 , and the concentration of N-acethyl-D-mannosamine is 4 to 12 mM.3. The medium according to claim 1 , wherein the concentration of uridine is 2 to 5 mM and the concentration of N-acethyl-D-mannosamine is 5 to 10 mM.4. The medium according to claim 1 , wherein the concentration of uridine is about 3 mM and the concentration of N-acethyl-D-mannosamine is about 8 mM.5. The medium according to claim 1 , further comprising:L-alanyl-L-glutamine.6. The medium according to claim 5 , wherein the concentration of L-alanyl-L-glutamine is 0.5 to 5 mM.7. The medium according to claim 5 , wherein the concentration of L-alanyl-L-glutamine is 1 to 3 mM.8. The medium according to claim 5 , wherein the concentration of L-alanyl-L-glutamine is about 2 mM.9. The medium according to claim 1 , wherein the medium does not include serum.10. A method of producing a glycoprotein claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'culturing a cell transformed with an exogenous DNA encoding the glycoprotein in the medium according to .'}11. The method according to claim 10 , wherein the exogenous DNA encoding the glycoprotein is incorporated into an expression vector such that the glycoprotein is expressed in a transformed cell.12. The method according to claim 10 , wherein the exogenous DNA encoding the glycoprotein is a human-derived DNA.13. The method according to claim 10 , wherein the ...

Подробнее
16-03-2017 дата публикации

COMPOSITIONS OF ADULT DISC STEM CELLS AND METHODS FOR THE TREATMENT OF DEGENERATIVE DISC DISEASE

Номер: US20170073640A1
Принадлежит:

This invention provides an isolated disc stem cell population, compositions, and methods of obtaining and growing the same. Moreover, this invention provides an isolated discosphere, compositions, and methods of obtaining and growing the same. An artificial disc containing the cells of the present invention is provided together with methods of making the same. This invention also provides a method of treating a subject having a herniated disc utilizing the cells and methods of the invention. 1. An isolated discosphere , wherein said discosphere is a free-floating in vitro structure comprising disc stem cells , disc progenitor cells , or a combination thereof.2. The isolated discosphere of claim 1 , wherein said discosphere comprises cells originating from a single disc stem cell.3. A composition comprising the discosphere of .4. The composition of claim 4 , wherein said composition further comprises a media.5. The composition of claim 5 , wherein said media is a serum free media.6. The composition of claim 5 , wherein said media further comprises FGF2 claim 5 , EGF claim 5 , SCF claim 5 , IL-6 claim 5 , IL-2 claim 5 , TGF-β claim 5 , LIF claim 5 , or a combination thereof.7. The composition of claim 5 , wherein said media additionally comprises insulin claim 5 , progesterone claim 5 , putrescine claim 5 , transferrin claim 5 , sodium selenite claim 5 , or a combination thereof.8. A method of producing the discosphere of claim 1 , comprising the step of growing a culture of nucleus pulposus cells in a serum free media comprising methylcellulose claim 1 , thereby producing a discosphere.9. The method of claim 9 , wherein said nucleus pulposus cells are human nucleus pulposus cells.10. The method of claim 9 , wherein said media further comprises FGF2 claim 9 , EGF claim 9 , SCF claim 9 , IL-6 claim 9 , IL-2 claim 9 , TGF-β claim 9 , LIF claim 9 , or a combination thereof.11. The method of claim 9 , wherein said media additionally comprises insulin claim 9 , ...

Подробнее
05-03-2020 дата публикации

DECREASING ORNITHINE METABOLISM TO DECREASE THE HIGH MANNOSE GLYCOFORM CONTENT OF RECOMBINANT PROTEINS

Номер: US20200071738A1
Принадлежит: Amgen Inc.

The present invention relates to a method for manipulating the high mannose glycoform content of recombinant glycoproteins by regulating ornithine metabolism during cell culture. 156.-. (canceled)57. A method of increasing high mannose glycoform content of a recombinant protein comprising culturing a host cell expressing the recombinant protein in a cell culture comprising one selected from the group consisting of ornithine , arginine , an ornithine aminotransferase inhibitor , a nitric oxide synthase inhibitor , an ornithine decarboxylase inhibitor , and an arginine decarboxylase inhibitor , wherein ornithine production in the host cell is increased when compared to the host cell expressing the recombinant protein is cultured in a cell culture lacking one selected from the group consisting of ornithine , arginine , an ornithine aminotransferase inhibitor , a nitric oxide synthase inhibitor , ornithine decarboxylase inhibitor , and an arginine decarboxylase inhibitor , andthe recombinant protein has an increased high mannose glycoform content than when the recombinant protein is expressed in the cell culture lacking one selected from the group consisting of ornithine, arginine, an ornithine aminotransferase inhibitor, a nitric oxide synthase inhibitor, ornithine decarboxylase inhibitor, and an arginine decarboxylase inhibitor.58. The method of claim 57 , whereinthe ornithine aminotransferase inhibitor is 5-fluoromethylornithine;{'sup': 'G', 'the nitric oxide synthase inhibitor is selected from the group consisting of 2-ethyl-2-thiopseudourea and N-Nitro-L-arginine and L-monomethyl-L-arginine; or'}the arginine decarboxylase inhibitor is asymmetric dimethyl-arginine.59. The method of claim 57 , wherein ornithine accumulation in the host cell is increased by the addition of at least 0.6 mM ornithine to the cell culture.60. The method of claim 57 , wherein the concentration of ornithine is selected from the group consisting of 0.6 to 14.8 mM; 6 to 14.8 mM; 0.6 mM claim ...

Подробнее
18-03-2021 дата публикации

AGGLOMERATED MICROBIOLOGICAL MEDIA

Номер: US20210079341A1
Автор: Liu Jie J., Xia Wensheng
Принадлежит: 3M INNOVATIVE PROPERTIES COMPANY

A method of making a flowable, dried agglomerated nutrient medium is provided. The method comprises introducing a nutrient component comprising a powdered nutrient, and an agglomeration liquid, into an agglomerator comprising a flow-through-type agglomeration chamber, wet-massing the nutrient component with the agglomeration liquid in the agglomeration chamber for a predetermined period of time to form agglomerated nutrient medium particles, and exposing the agglomerated nutrient medium particles to drying conditions for a period of time to form the dried, agglomerated nutrient medium. The nutrient component facilitates the growth of a microorganism. Compositions, articles, and kits comprising the flowable, dried agglomerated nutrient medium are also provided. 2. The method of claim 1 , wherein the agglomeration liquid comprises a solvent having a dissolved nutrient that facilitates the growth of a microorganism.3. The method of claim 1 , wherein introducing a nutrient component comprises introducing a substantially uniform mixture of two or more powdered nutrients.4. The method of claim 1 , wherein one or more powdered nutrient is selected from the group consisting of a protein claim 1 , a carbohydrate claim 1 , a salt and a mixture of any two or more of the foregoing powdered nutrients.5. The method of claim 1 , further comprising the step of subjecting the dried agglomerated nutrient medium to a process that reduces the number of viable microorganisms in the dried agglomerated nutrient medium.6. The method of wherein subjecting the dried agglomerated nutrient medium to a process that reduces the number of viable microorganisms comprises exposing the dried agglomerated nutrient medium to ionizing radiation or to ethylene oxide vapor.7. The method of claim 1 , wherein the subpopulation of the particles having a size distribution range being about 149 microns to 1000 microns is a second subpopulation claim 1 , and further comprising a step of isolating a first ...

Подробнее
24-03-2016 дата публикации

STEM CELL COMPOSITION FOR VENOUS ADMINISTRATION

Номер: US20160081917A1
Принадлежит:

The present invention relates to a stem cell composition for intravenous administration, which contains stem cells at a concentration of 1×10to 5×10cells/ml, in which the stem cells have a diameter of 10-20 μm and are present as single cells. The stem cell composition according to the present invention is suitable for intravenous administration, and enables the stem cells to securely reach a target tissue after intravascular administration so as to exhibit their activity in the target tissue. Thus, it can significantly increase the therapeutic effects of the stem cells. 1. A stem cell composition for intravenous administration , which contains stem cells at a concentration of 1×10to 5×10cells/ml , in which the stem cells have a diameter of 10-20 μm and are present as single cells.2. The stem cell composition of claim 1 , wherein the stem cells have a diameter of 10-15 μm.3. The stem cell composition of claim 1 , wherein the stem cells contained in the stem cell composition for intravenous administration are prepared by the culture thereof in a medium containing a basal medium; and at least two components selected from the group consisting of N-acetyl-L-cysteine (NAC) claim 1 , ascorbic acid claim 1 , insulin or insulin-like factor claim 1 , hydrocortisone claim 1 , dexamethasone claim 1 , bFGF (basic fibroblast growth factor) claim 1 , heparan sulfate claim 1 , 2-mercaptoethanol claim 1 , EGF (epidermal growth factor) claim 1 , and antioxidant.4. The stem cell composition of claim 3 , wherein the basal medium is selected from the group consisting of M199/F12 (mixture) (GIBCO) claim 3 , MEM-alpha medium (GIBCO) claim 3 , low-concentration glucose-containing DMEM medium (Welgene) claim 3 , MCDB 131 medium (Welgene) claim 3 , IMEM medium (GIBCO) claim 3 , K-SFM claim 3 , DMEM/F12 medium claim 3 , PCM medium claim 3 , and MSC expansion medium (Chemicon).5. The stem cell composition of claim 3 , wherein the antioxidant is selected from the group consisting of selenium ...

Подробнее
14-03-2019 дата публикации

Animal Protein-Free Media for Cultivation of Cells

Номер: US20190078051A1
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. A method for cultivating cells , comprising the steps of:(a) providing an animal protein-free cell culture medium;(b) adding a supplement to the animal protein-free cell culture medium comprising at least one polyamine and at least one protein hydrolysate derived from the group consisting of plants and yeast, wherein the resultant concentration of the at least one polyamine in the animal protein-free cell culture medium ranges from about 0.5 to about 30 mg/L; and(c) propagating the cells in the animal protein-free cell culture medium to form a cell culture.2. The method according to claim 1 , wherein the cells are selected from the group consisting of mammalian cells claim 1 , insect cells claim 1 , avian cells claim 1 , bacterial cells claim 1 , and yeast cells.3. The method according to claim 2 , wherein the mammalian cells are CHO cells.4. The method according to claim 3 , wherein the CHO cells are propagated in suspension.5. The method according to claim 4 , wherein the cell culture is a chemostat suspension culture.6. The method according to claim 1 , wherein the cells are cultivated by a method selected from the group consisting of batch-cultivation claim 1 , feed-batch-cultivation claim 1 , perfusion cultivation claim 1 , and chemostat-cultivation.7. The method according to claim 1 , wherein the polyamine is selected from the group consisting of cadaverine claim 1 , putrescine claim 1 , spermidine claim 1 , spermine claim 1 , agmatine claim 1 , ornithine ...

Подробнее
24-03-2016 дата публикации

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Номер: US20160083689A1
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. An animal protein-free medium cell culture medium comprising at least one polyamine and at least one protein hydrolysate , wherein the hydrolysate is derived from plants or yeast.2. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to about 10 mg/L.3. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is cadaverine claim 1 , putrescine claim 1 , spermidine claim 1 , spermine claim 1 , agmatine claim 1 , or ornithine; or a combination thereof.4. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is putrescine in a concentration ranging from about 0.5 to about 10 mg/L claim 1 , and the protein hydrolysate is soy hydrolysate in a concentration ranging from about 0.05% (w/v) to about 5% (w/v).5. The animal protein-free cell culture medium of claim 1 , wherein the polyamine originates from a source other than a protein hydrolysate.6. The animal protein-free cell culture medium of claim 1 , wherein the polyamine is present in the culture medium in a concentration ranging from about 0.5 to 30 mg/L.7. The animal protein-free cell culture medium of claim 1 , wherein the protein hydrolysate is present in the culture medium in a total concentration ranging from about 0.05% (w/v) to about 5% (w/v) for all protein hydrolysates.8. The animal protein-free cell culture medium of claim 1 , wherein the protein hydrolysate is ...

Подробнее
23-03-2017 дата публикации

MATERIALS AND METHODS FOR EXPANSION OF STEM CELLS

Номер: US20170081638A1
Автор: MA TENG
Принадлежит:

The subject invention concerns novel and translatable materials and methods for expansion of stem cells, such as mesenchymal stem cells (MSC), that significantly improve translational success of the cells in the treatment of various conditions, such as stroke. The subject invention utilizes cell self-aggregation as a non-genetic means to enhance their therapeutic potency in a microcarrier bioreactor. The subject invention integrates a cell aggregation process in a scalable bioreactor system. In one embodiment of the method, thermally responsive microcarriers (TRMs) are utilized in conjunction with a bioreactor system. Cells are cultured in a container or vessel in the presence of the TRMs wherein cells adhere to the surface of the TRMs. Once cells are adhered to the TRMs they can be cultured at a suitable temperature for cell growth and expansion, e.g., at about 37° C. After a period of time sufficient for cell growth and expansion on the TRMs, the cell culture temperature is reduced so that the cells detach from the TRMs. The detached cells are allowed to form cell clusters that are then cultured under conditions such that the clusters aggregate to form 3D aggregates. The 3D aggregates can be collected and treated to dissociate the cells (e.g., using enzymatic treatment, such as trypsinization). Dissociated cells can then be used for transplantation in methods of treatment or for in vitro characterization and study. 1. A method for expanding a stem cell , wherein said method comprises culturing stem cells in a bioreactor system in the presence of a thermally responsive microcarrier (TRM) , wherein stem cells adhere to the surface of said TRM; growing the adhered stem cells for a sufficient period of time for the stem cells to increase in numbers; detaching the stem cells from the TRM by reducing the culture temperature to a critical solution temperature that results in said adhered cells detaching from the surface of said TRM; providing said detached cells ...

Подробнее
31-03-2022 дата публикации

Method for Treating and/or Preventing Bacteriophage Lysis During Fermentation

Номер: US20220099672A1
Автор: ALIBEK Ken, FARMER Sean
Принадлежит:

The subject invention relates to enhancing for the production of microorganisms and/or their growth by-products by treating and/or preventing bacteriophage contamination of bacterial cultures. Advantageously, the methods can help reduce the likelihood of total and/or partial culture loss through the direct control of bacteriophages and/or prophages that may be present in the culture. In certain embodiments, the method comprise applying an antiviral composition comprising, for example, ribavirin, to the nutrient medium in which a microorganism is being cultivated. 1. A method of cultivating a bacterial strain and/or producing a growth by-product of a bacterial strain , the method comprising:a) inoculating a nutrient medium with the strain;b) applying an antiviral composition to the nutrient medium; andc) cultivating the strain to produce a culture having a desired cell density and/or a desired concentration of the growth by-product,wherein the antiviral composition comprises one or more antiviral compounds that interfere with viral DNA or RNA synthesis and/or interfere with viral DNA or RNA polymerase activity, andwherein the antiviral composition controls a bacteriophage in the culture but does not harm the bacterial strain.2. The method of claim 1 , wherein the antiviral composition comprises ribavirin.3Bacillus, Azotobacter, PseudomonasRhodococcus.. The method of claim 1 , wherein the bacteria is a strain of or4. The method of claim 1 , wherein the nutrient medium is solid or liquid.5. The method of claim 1 , wherein the nutrient medium comprises sources of nitrogen and carbon.6. The method of claim 1 , wherein about 0.5 g/L to about 10.0 g/L of the antiviral composition is applied to the nutrient medium.7. The method of claim 1 , wherein the antiviral composition is applied prior to claim 1 , or concurrently with claim 1 , inoculating the nutrient medium.8. The method of claim 1 , wherein the antiviral composition is applied after inoculating the nutrient medium. ...

Подробнее
31-03-2016 дата публикации

Mobilizing cells expressing a type 4 cxc chemokine receptor with 4-amino pyrimidine compounds

Номер: US20160090394A1
Принадлежит: Taigen Biotechnology Co Ltd

A method of mobilizing cells expressing the type 4 CXC chemokine receptor into the peripheral circulation by contacting them with an effective amount of a compound of formula (I) shown below (each variable in the formula being defined in the Specification): The method can be used to treat cancer and myocardial infarction.

Подробнее
21-03-2019 дата публикации

Control of protein glycosylation by culture medium supplementation and cell culture process parameters

Номер: US20190085369A1
Принадлежит: Biogen MA Inc, Samsung Bioepis Co Ltd

The present invention pertains to a cell culture medium comprising media supplements that are shown to control recombinant protein glycosylation and/or cell culture in a controlled or modulated (shifted) temperature to control recombinant protein glycosylation and/or cell culture with controlled or modulated seed density to control recombinant protein glycosylation, and methods of using thereof. The present invention further pertains to a method of controlling or manipulating glycosylation of a recombinant protein of interest in a large scale cell culture.

Подробнее
30-03-2017 дата публикации

MAMMALIAN EMBRYONIC STEM CELL ISOLATED FROM A HOMOGENEOUS PLURIPOTENT OUTGROWTH OF A MAMMALIAN PRE-IMPLANTATION EMBRYO

Номер: US20170088816A1
Принадлежит:

The present invention relates to a method of isolating a pluripotent cell from a pre-implantation embryo including one or more pluripotent cells. The method includes propagating the one or more pluripotent cells from the embryo under conditions that allow undifferentiated growth of the one or more pluripotent cells and do not allow growth of non-pluripotent cells from the embryo. 1110-. (canceled)111. A mammalian pluripotent embryonic stem cell , wherein the stem cell is isolated from a mammalian pre-implantation embryo which includes one or more pluripotent embryonic stem cells , and wherein the stem cell is isolated from the mammalian pre-implantation embryo by a method comprising the steps of:(i) selecting the pre-implantation embryo in a blastocyst stage of development, wherein the inner cell mass of the pre-implantation embryo has yet to differentiate into the epiblast and hypoblast;(ii) depressing, embedding or flattening all of the pre-implantation embryo into a feeder cell layer causing all cells of the embryo to make contact with the feeder cell layer;(iii) culturing the depressed, embedded or flattened pre-implantation embryo in a medium that is free of serum to (a) inhibit differentiation of the one or more pluripotent embryonic stem cells and allow undifferentiated growth of the one or more pluripotent embryonic stem cells resulting in formation of a homogeneous pluripotent embryonal outgrowth and (b) not allow growth of non-pluripotent cells from the pre-implantation embryo; and(iv) isolating a mammalian pluripotent embryonic stem cell from the one or more pluripotent embryonic stem cells.112. The mammalian pluripotent embryonic stem cell of claim 111 , wherein the medium includes a serum replacement and/or albumin.113. The mammalian pluripotent embryonic stem cell of claim 112 , wherein the medium includes 5 to 25% serum replacement.114. The mammalian pluripotent embryonic stem cell of claim 111 , wherein the medium includes L-glutamine claim 111 , ...

Подробнее
19-03-2020 дата публикации

METHODS FOR DIFFERENTIATING PLURIPOTENT STEM CELLS IN DYNAMIC SUSPENSION CULTURE

Номер: US20200087622A1
Принадлежит: LINEAGE CELL THERAPEUTICS, INC.

Methods for differentiating pluripotent stem cells to neuroectoderm in dynamic suspension culture using small molecule or protein inhibitors of TGFβ/Activin/Nodal signaling and BMP signaling are provided. Also provided are methods and protocols for differentiating pluripotent stem cells such as human embryonic stem cells first to neuroectoderm, then further to glial progenitor cells, and further to oligodendrocyte progenitor cells (OPCs), and compositions obtained thereby. The methods of the present disclosure reproducibly produce neuroectoderm progenitor cells by day 7 of the differentiation process, glial progenitor cells by day 21 of the differentiation process and OPCs by day 42 of the differentiation process. 1. A method for obtaining a population of cells comprising glial progenitor cells from undifferentiated human pluripotent stem cells , the method comprising:a) obtaining a suspension culture of non-embryoid body (non-EB) aggregates of undifferentiated human pluripotent stem cells, wherein the human pluripotent stem cells remain in an undifferentiated state;b) culturing the non-EB aggregates from a) in dynamic suspension in the presence of at least one inhibitor of transforming growth factor beta (TGFβ)/Activin/Nodal signaling and at least one inhibitor of bone morphogenetic protein (BMP) signaling for a first time period, thereby inducing differentiation to neuroectoderm;c) culturing the non-EB aggregates from b) in dynamic suspension in the presence of retinoic acid and at least one agonist of Smoothened receptor for a second time period; andd) culturing the aggregates from c) in dynamic suspension in the presence of basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) for a further time period, until the cells have matured into glial progenitor cells.2. The method of claim 1 , further comprising an additional step of harvesting the non-EB aggregates from d) and plating them onto a substrate claim 1 , thereby resulting in migration of ...

Подробнее
12-05-2022 дата публикации

Culture medium for mammalian expanded potential stem cells, composition, and methods thereof

Номер: US20220145264A1
Принадлежит: University of Hong Kong HKU

A culture medium is provided for establishing expanded potential stem cell (EPSC) lines for mammals. Methods are provided using the medium for the in vitro conversion and maintenance of cells, including pluripotent cells into EPSCs.

Подробнее
28-03-2019 дата публикации

Compositions and methods for differentiating stem cells into cell populations comprising beta-like cells

Номер: US20190093083A1
Принадлежит: Regenerative Medical Solutions Inc

Methods, kits, compositions, and systems are provided for culturing pluripotent stem cells to produce populations of cells comprising beta-like cells (e.g., pancreatic lineage, glucose-responsive, and/or insulin-producing). In particular, culture conditions are provided that result in the generation of beta-like cells from a starting culture of human pluripotent stem cells.

Подробнее
12-05-2022 дата публикации

Oligonucleotides for inducing paternal ube3a expression

Номер: US20220146496A1
Принадлежит: Hoffmann La Roche Inc

The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

Подробнее
16-04-2015 дата публикации

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLS

Номер: US20150104867A1
Принадлежит:

The present invention relates to animal protein-free cell culture media comprising polyamines and a plant- and/or yeast-derived hydrolysate. The invention also relates to animal protein-free culturing processes, wherein cells can be cultivated, propagated and passaged without adding supplementary animal proteins in the culture medium. These processes are useful in cultivating cells, such as recombinant cells or cells infected with a virus, and for producing biological products by cell culture processes. 1. A method for cultivating Chinese hamerster ovary (CHO) cells in soy hydrolysate-containing animal protein-free medium supplemented with purescine to overcome inhibitory effects on cell growth due to soy hydrolysate lot variation , said method comprising the steps of:(a) providing an animal protein-free cell culture medium comprising soy hydrolysate and putrescine, wherein the putrescine is added to said culture medium in a concentration ranging from 0.5 mg/L to 10 mg/L, and the soy hydrolysate is present in a concentration ranging from 0.05% (w/v) to 0.5% (w/v); and(b) propagating the cells in the medium to form a cell culture.2. The method according to claim 1 , wherein the cells are cultivated by a method selected from the group consisting of batch-cultivation claim 1 , feed-batch-cultivation claim 1 , perfusion cultivation claim 1 , and chemostat-cultivation. This application is a continuation of U.S. patent application Ser. No. 13/864,118 filed Apr. 16, 2013, which is a continuation of U.S. patent application Ser. No. 12/965,111 filed Dec. 10, 2010, issued U.S. Pat. No. 8,440,408; which is a continuation of U.S. patent application Ser. No. 11/858,844, filed Sep. 20, 2007, now abandoned; which is a division of U.S. patent application Ser. No. 10/976,399, filed Oct. 29, 2004, now abandoned; each of which applications is herein incorporated by reference in its entirety for all purposes.The present invention relates to animal protein-free cell culture media ...

Подробнее
16-04-2015 дата публикации

NUCLEOSIDE SUPPLEMENTATION TO PROMOTE CELLULAR FUNCTION, GENETIC STABILITY AND REGENERATIVE APPLICATIONS

Номер: US20150105343A1
Принадлежит:

In various embodiments, a cell culture medium, or a nucleoside cocktail transmission (NCT) medium for the culture of stem cells with improved genetic stability, cellular function and regeneration ability is provided. Illustrative culture media comprise a basal culture medium for stem cells, where the culture medium is supplemented with one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. Illustrative NCT media comprise a delivery vehicle (e g. skin creams or other vehicle) containing one or more nucleoside triphosphates (e.g., dNTPs and/or NPs) or one or more precursors thereof. The NCT medium provides, inter alia, direct delivery of nucleoside cocktails into human tissues (such as skin) for regenerative, cosmetic and/or therapeutic purposes. 1. A cell culture medium for the culture of stem cells with improved genetic stability , said culture medium comprising:a basal culture medium for stem cells, where said culture medium is supplemented with one or more nucleoside triphosphates or one or more precursors thereof.2. A nucleoside cocktail transmission (NCT) medium for improving somatic or stem cell genetic stability said medium comprising:a cosmetic or pharmaceutical delivery vehicle; andone or more nucleoside triphosphates or precursors thereof.3. The cell culture medium of claim 1 , wherein said one or more nucleoside triphosphates are independently selected from the group consisting of deoxyadenosine triphosphate (dATP) claim 1 , deoxyguanosine triphosphate (dGTP) claim 1 , deoxycytidine triphosphate (NCTP) claim 1 , deoxythymidine triphosphate (dTTP) deoxyuridine triphosphate claim 1 , adenosine triphosphate (ATP) claim 1 , guanosine triphosphate (GTP) claim 1 , cytidine triphosphate (CTP) claim 1 , 5-methyluridine triphosphate (m5UTP) claim 1 , and uridine triphosphate (UTP).4. The nucleoside cocktail transmission medium of claim 2 , wherein said one or more nucleoside triphosphates are independently selected from the ...

Подробнее
26-03-2020 дата публикации

HUMAN IPSC-DERIVED VASCULAR-RELATED AND HEMATOPOETIC CELLS FOR THERAPIES AND TOXICOLOGY/DRUG SCREENINGS

Номер: US20200095544A1
Принадлежит:

Described herein are cells, cell culture methods, and cell culture media compositions useful for producing and maintaining iPSC-derived cell lines that are of higher purity and maintain cell type integrity better than current iPSC-derived cell lines. Also disclosed are methods of using the described cells and media, such as therapeutic methods of use for the described cells. The described cells include iPSC-derived mesodermal precursor cells (MPC), which itself may differentiate into at least four different cell types. When cultured under appropriate conditions, the mesodermal precursor cells can be used to produce hematopoietic stem cells (HSC), mesenchymal stem cells (MSC), smooth muscle cells (SMC), or unlimited functional endothelial cells (UFEC). One characteristic that makes the described cells desirable is that they can be maintained in culture for a number of days, or passages, without changing phenotype through differentiation. 1. A method of producing mesodermal precursor cells from induced pluripotent stem cells (iPSC) , comprising incubating the iPSCs in a cell culture medium comprising:Iscove's modified Dulbecco's medium (IMDM),Ham's F-12 Nutrient Mix, with L-alanyl-L-glutamine additive,Albumin,α-monothioglycerol,protein-free hybridoma mixture II,L-ascorbic acid 2-phosphate,L-alanyl-L-glutamine,Antibiotic,insulin-transferrin-selenium-ethanolamine supplement,bone morphogenic protein 4,vascular endothelial growth factor, andbasic fibroblast growth factor.2. The method of claim 1 , wherein the cell culture medium comprises cholesterol lipids.38-. (canceled)9. The method of claim 1 , wherein the antibiotic is selected from the group consisting of penicillin claim 1 , streptomycin claim 1 , and a mixture of penicillin and streptomycin.10. (canceled)11. (canceled)12. The method of claim 1 , wherein the concentration of albumin is about 5 mg/ml.13. The method of claim 1 , wherein the concentration of α-monothioglycerol is from about 350 to about 450 μM.14. The ...

Подробнее
08-04-2021 дата публикации

MODALITIES FOR THE TREATMENT OF DEGENERATIVE DISEASES OF THE RETINA

Номер: US20210102164A1
Автор: KLIMANSKAYA Irina V.

This invention relates to methods for improved cell-based therapies for retinal degeneration and for differentiating human embryonic stem cells and human embryo-derived into retinal pigment epithelium (RPE) cells and other retinal progenitor cells. 1. A method of treating or preventing retinal degeneration , comprising use of a cell selected from the group consisting of at least one of: RPE cells , RPE-like cells , RPE or RPE-like progenitors derived from mammalian embryonic stem cells.2. The method of claim 1 , wherein the condition of retinal degeneration is selected from the group consisting of at least one of: retinitis pigmentosa and macular degeneration.3. The method of claim 1 , further comprising transplantation of the cell by vitrectomy surgery into the subretinal space of the eye.4. The method of claim 3 , wherein the cells are transplanted in a suspension claim 3 , matrix claim 3 , or substrate.5. The method of claim 2 , wherein the retinitis pigmentosa is associated with an animal model.6. The method of claim 5 , where in the animal model is selected from the group consisting of: rd mouse claim 5 , RPE-65 knockout mouse claim 5 , tubby-like mouse claim 5 , RCS rat claim 5 , Abyssinian cat claim 5 , cone degeneration “cd” dog claim 5 , progressive rod-cone degeneration “prcd” dog claim 5 , early retinal degeneration “erd” dog claim 5 , rod-cone dysplasia 1 claim 5 , 2 & 3 “rcd1 claim 5 , rcd2 and rcd3” dogs claim 5 , photoreceptor dysplasia “pd” dog claim 5 , and Briard “RPE-65” dog.7. The method of claim 6 , wherein the outcome of the therapy in the animal model is evaluated using one or more of behavioral tests claim 6 , fluorescent angiography claim 6 , histology claim 6 , and functional testing such as measuring the ability of the cells to perform phagocytosis (photoreceptor fragments) claim 6 , vitamin A metabolism claim 6 , tight junctions conductivity claim 6 , or evaluation using electron microscopy.8. A method for the spontaneous differentiation ...

Подробнее
08-04-2021 дата публикации

MESENCHYMAL STEM CELL STORING OR TRANSPORT FORMULATION AND METHODS OF MAKING AND USING THE SAME

Номер: US20210102171A1
Принадлежит:

The present invention relates to a mesenchymal stem cell storing or transport formulation, a method of preparing the mesenchymal stem cell toring or transport formulation as well as to methods of using the mesenchymal stem cell storing or transport formulation. Such methods include a method of transporting mesenchymal stem cells in this storing or transport formulation as well as a method of treating a subject having a disease, the method comprising topically administering mesenchymal stem cells that have been stored or transported in this storing or transport formulation. Also concerned is a unit dosage of the mesenchymal stem cells. 1. A method of preparing a mesenchymal stem cell storing or transport formulation , wherein the formulation comprises about 0.5 to about 10 million mesenchymal stem cells , the method comprisinga) suspending mesenchymal stem cells in a pre-defined volume of a crystalloid solution, wherein the crystalloid solution comprises about 0.5% to about 5% (w/v) serum albumin, thereby obtaining a first cell suspension,b) determining the concentration of the mesenchymal stem cells in the first cell suspension, and determining the volume of the first cell suspension needed to prepare a formulation comprising about 0.5 to about 10 million mesenchymal stem cells,c) mixing the determined volume of the first cell suspension with a volume of a liquid carrier, wherein said liquid carrier comprises about 0.5% to about 5% (w/v) serum albumin as well asi) Trolox;{'sup': '+', 'ii) Na;'}{'sup': '+', 'iii) K;'}{'sup': '2+', 'iv) Ca,'}{'sup': '2+', 'v) Mg'}{'sup': '−', 'vi) Cl;'}{'sub': 2', '4, 'sup': '−', 'vii) HPO;'}viii) HEPES;ix) Lactobionate;x) Sucrose;xi) Mannitol;xii) Glucose;xiii) Dextran-40;xiv) Adenosine, andxv) Glutathione,thereby obtaining the mesenchymal stem cell storing or transport formulation comprising about 0.5 to about 10 million mesenchymal stem cells.2. The method of claim 1 , wherein the pre-defined volume of the crystalloid solution used ...

Подробнее
02-06-2022 дата публикации

COMPOSITIONS AND METHODS FOR INCREASING T CELL FUNCTION

Номер: US20220168271A1
Принадлежит:

An agent for use in reducing T cell exhaustion and/or increasing T cell function, and/or boosting immunity, wherein the agent is selected from the group consisting of nicotinamide riboside, vitamin B12, a urolithin, manganese, serine, glycine, arginine, asparagine, and a combination of two or more thereof. 1. A method for use in reducing T cell exhaustion and/or increasing T cell function , and/or boosting immunity , comprising an agent selected from the group consisting of nicotinamide riboside , vitamin B12 , a urolithin , manganese , serine , glycine , arginine , asparagine , and a combination of two or more thereof that is administered to a subject in need of same.2. A method for use in the treatment of (a) a bacterial or viral infection , or the prevention or treatment of (b) cancer , comprising administering an agent selected from the group consisting of nicotinamide riboside , vitamin B12 , a urolithin , manganese , serine , glycine , arginine , asparagine , and a combination of two or more thereof to a subject in need of same.3. The method according to claim 1 , wherein the agent is used as part of a method of adoptive T cell transfer.46-. (canceled)7. The method according to claim 1 , wherein the use increases T cell levels in a subject.8. The method according to claim 1 , wherein the agent is nicotinamide riboside or vitamin B12 claim 1 , or a combination comprising nicotinamide riboside and/or vitamin B12.9. The method according to claim 1 , wherein the combination is selected from the group consisting of (a) nicotinamide riboside claim 1 , a urolithin and manganese; (b) nicotinamide riboside claim 1 , vitamin B12 and manganese; (c) nicotinamide riboside claim 1 , a urolithin and vitamin B12; (d) serine claim 1 , glycine and vitamin B12; and (e) a urolithin claim 1 , vitamin B12 and manganese (f) nicotinamide riboside claim 1 , vitamin B12 claim 1 , a urolithin and claim 1 , manganese claim 1 , and preferably wherein the combination is nicotinamide ...

Подробнее
02-06-2022 дата публикации

HUMAN CARDIOMYOCYTE SEPARATION REAGENT, CULTURE MEDIUM, SEPARATION METHOD, AND CULTURE METHOD

Номер: US20220169989A1
Принадлежит:

Provided are a composition containing (−)-Blebbistain and/or para-Blebbistain, a kit comprising the composition, and a cardiomyocyte culture method using the composition as a culture medium. Also provided is a use of (−)-Blebbistain and/or para-Blebbistain in preparation of a cardiomyocyte isolation reagent or cardiomyocyte culture reagent. 2. The composition of claim 1 , comprising the following components: 1-50 μM (−)-Blebbistatin claim 1 , 5-50 mM glucose claim 1 , 0.1-20 mM sodium pyruvate claim 1 , 0.1-20 mM creatine claim 1 , 5-50 mM β-aminoethanesulfonic acid claim 1 , 0.5-10 mM 4-hydroxyethyl piperazine ethanesulfonic acid (HEPES) claim 1 , 10-500 U/ml penicillin claim 1 , 10-500 μg/ml streptomycin claim 1 , 0.1-20 mM magnesium chloride claim 1 , 0.1-20 mM potassium chloride claim 1 , 10-500 mM sodium chloride claim 1 , 0.5-30 mM sodium dihydrogen phosphate claim 1 , and an appropriate amount of NaOH to make the pH of the composition be 7.0-7.8.3. A method for isolating cardiomyocytes claim 1 , comprising the steps of calcium-free perfusion claim 1 , digestion and cell collection claim 1 , wherein the composition of is used in the steps of calcium-free perfusion claim 1 , digestion and cell collection.4. A composition obtained by adding (−)-Blebbistatin and/or para-aminoblebbistatin claim 1 , antibiotics and sera to M199 medium series claim 1 , MEM medium series claim 1 , and DMEM medium series.5. The composition of claim 4 , which is obtained by adding the following components to M199 medium claim 4 , MEM-GlutaMAX medium or MEM-4-hydroxyethyl piperazine ethanesulfonic acid-GlutaMAX medium:(−)-Blebbistatin and/or para-aminoblebbistatin, wherein in the composition, the concentration of (−)-Blebbistatin is 1-50 μM, and the concentration of para- aminoblebbistatin is 1-100 μM;penicillin, and/or streptomycin, and/or Primocin, wherein the concentration of penicillin in the composition is 10-500 U/ml, the concentration of streptomycin in the composition is 10-500 ...

Подробнее
21-04-2016 дата публикации

METHODS AND COMPOSITIONS FOR GENERATING OR MAINTAINING PLURIPOTENT CELLS

Номер: US20160108369A1
Принадлежит: Regeneron Pharmaceuticals, Inc.

Methods and compositions are provided for generating or maintaining human iPS cells in culture. Methods include the use of a low osmolality medium to make human iPS cells, or use of a low osmolality medium to maintain human iPS cells. Methods for making targeted genetic modification to human iPS cells cultured in low osmolality medium are also included. Compositions include human iPS cells cultured and maintained using the low osmolality medium defined herein. 1. An in vitro culture comprising:(a) a population of hiPSCs; and (i) a leukemia inhibitory factor (LIF) polypeptide;', '(ii) a glycogen synthase kinase 3 (GSK3) inhibitor; and', '(iii) a MEK inhibitor;', 'wherein the base medium has an osmolality of about 180 mOsm/kg to about 250 mOsm/kg., '(b) a low osmolality medium comprising a base medium and supplements, wherein the low osmolality medium comprises2. The in vitro culture of claim 1 , wherein the hiPSCs:(a) comprise naïve or naïve-looking hiPSCs;(b) express one or more pluripotency markers;(c) display a morphology characterized by compact dome-shaped colonies;(d) can differentiate into cells of any one of the endoderm, ectoderm, or mesoderm germ layers;(e) have a doubling time of between about 16 hours and about 24 hours; or(f) any combination of (a) to (e).3. The in vitro culture of claim 1 , wherein the hiPSCs have a normal karyotype.4. The in vitro culture of claim 2 , wherein the pluripotency markers comprise NANOG claim 2 , alkaline phosphatase claim 2 , or a combination thereof.5. The in vitro culture of claim 1 , wherein the hiPSCs are derived from non-pluripotent cells transformed to express a pluripotent state.6. The in vitro culture of claim 5 , wherein the transformed cells express reprogramming genes comprising Oct4 claim 5 , Sox2 claim 5 , Klf4 claim 5 , Myc claim 5 , or any combination thereof.7. The in vitro culture of claim 5 , wherein the transformed cells comprise primed hiPSCs.8. The in vitro culture of claim 5 , wherein the transformed ...

Подробнее
02-04-2020 дата публикации

METHOD FOR PRODUCING RETINAL TISSUE AND RETINA-RELATED CELLS

Номер: US20200102535A1
Принадлежит:

The present invention provides a method for producing a retinal progenitor cell, including (1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and (2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog signal transduction pathway but containing a substance acting on the BMP signal transduction pathway, thereby obtaining an aggregate containing retinal progenitor cells. 1. A method for producing a retinal progenitor cell , comprising(1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells, and(2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or serum-containing medium each being free of a substance acting on the Sonic hedgehog (Shh) signal transduction pathway that can enhance signal transduction mediated by Shh at a concentration exerting an adverse influence on the selective differentiation into retinal progenitor cell and retinal tissue and containing a substance acting on the bone morphogenic protein (BMP) signal transduction pathway that can enhance signal transduction pathway mediated by BMP at a concentration necessary for differentiation induction into retinal cells from day 1 or later from the start of the floating culture in step (1) until a cell expressing retina and anterior neural fold homeobox (Rax) gene appears, thereby obtaining an aggregate containing retinal progenitor cells.2. A method for producing a retinal tissue , comprising(1) a first step of subjecting pluripotent stem cells to floating culture in a serum-free medium to form an aggregate of pluripotent stem cells,(2) a second step of subjecting the aggregate formed in step (1) to floating culture in a serum-free medium or ...

Подробнее
11-04-2019 дата публикации

METHODS OF EXPANDING MYELOID CELL POPULATIONS AND USES THEREOF

Номер: US20190106680A1
Принадлежит:

The present disclosure relates to a method of expanding myeloid progenitor cells by culturing an initial population of cells in a medium comprising a mixture of cytokines and growth factors that promote growth and expansion of the myeloid progenitor cells. The expanded cell population provides a source of cells as therapeutic treatments for neutropenia and/or thrombocytopenia arising in patients subjected to myeloablative therapy and hematopoietic stem cell transplantation. 1. A method of improving impaired hematopoiesis in a human , comprising ,administering to the human a composition comprising human allogeneic myeloid progenitor cells derived from multiple unrelated donors in an amount sufficient to improve hematopoiesis in the human, wherein there is at least a partial mismatch at a major histocompatability complex (MHC) gene between the donors and the human.2. The method of claim 1 , wherein the composition has less than 10% hematopoietic stem cells (HSCs).3. The method of claim 1 , wherein human allogeneic myeloid progenitor cells are expanded human allogeneic myeloid progenitor cells.4. The method of claim 1 , wherein the myeloid progenitor cells comprise common myeloid progenitor cells.5. The method of claim 1 , wherein myeloid progenitor cells in the composition are at least 25% of total cells in the composition.6. The method of claim 1 , wherein the human is undergoing hematopoietic stem cell (HSC) transplantation.7. The method of claim 6 , wherein the expanded myeloid progenitor cells are administered after the HSC transplantation.8. The method of claim 6 , wherein the expanded myeloid progenitor cells are administered concurrently with HSC transplantation.9. The method of claim 1 , wherein the human is neutropenic.10. The method of claim 1 , wherein the human is suffering from thrombocytopenia.11. The method of claim 10 , wherein the expanded myeloid progenitor cells are administered adjunctively with a therapeutic composition for treating complications ...

Подробнее
09-06-2022 дата публикации

Methods for producing regulatory b cells and uses thereof

Номер: US20220175837A1
Принадлежит: University of Texas System

Provided herein are methods for expanding populations of regulatory B cells comprising engineering a population of B cells to express CD40 ligand. Also provided herein are methods of treating immune disorders with the regulatory B cells.

Подробнее
26-04-2018 дата публикации

Immunotherapy of Cancer by Induction of Immunologically-Mediated Selective Killing of Tumor Vasculature Using Modified Endothelial Cells and Progenitors Thereof

Номер: US20180110847A1
Принадлежит:

Disclosed are methods, protocols, and compositions of matter useful for treatment of cancer by elicitation of immunity towards tumor blood vessels. In one embodiment, the invention teaches the stimulation of expression of tumor blood vessel associated antigens in cells derived from endothelial progenitor cells, through culture of cells in conditions resembling the tumor microenvironment. In another embodiment, the invention teaches increasing immunogenicity of endothelial progenitor cells or progeny thereof through treatment with agents such as interferon gamma, which are capable of upregulating histocompatibility antigens, which allow for allogeneic rejection upon administration. In another embodiment, the invention teaches immunization with endothelial progenitor cells or progeny thereof treated under conditions to resemble tumor blood vessels, in which administered cells are purposely mismatched with recipient HLA in order to provide for enhanced allogenicity. In one embodiment, purposeful mismatching is accomplished through transfection or “cell painting” of molecules capable of eliciting an immunological response. 1. A method of treating cancer comprising the steps of: a) obtaining endothelial progenitor cells; b) culturing the endothelial progenitor cells under conditions resembling the tumor microenvironment; and c) administering products of the cultured endothelial progenitor cells in a manner to stimulate an immune response capable of cross-reacting with tumor associated endothelial cells.2. The method of claim 1 , wherein the endothelial progenitor cell is derived from placental tissue.3. The method of claim 1 , wherein the endothelial progenitor cell is HLA mismatched to the cancer patient in need of treatment.4. The method of claim 1 , wherein the endothelial progenitor cell is treated with interferon gamma at concentrations and duration sufficient to increase expression of HLA I and HLA II.5. The method of claim 1 , wherein the endothelial progenitor ...

Подробнее
09-06-2022 дата публикации

CELL CULTURE MEDIUM FOR EUKARYOTIC CELLS

Номер: US20220177832A1
Принадлежит: Regeneron Pharmaceuticals, Inc.

Cell culture media are provided herein as are methods of using the media for cell culture and protein production from cells. 1. A method for culturing eukaryotic cells for increasing production of aflibercept , comprising the steps of:culturing eukaryotic cells expressing aflibercept in culture medium;supplementing the cell culture medium with 5-methylthioadenosine, wherein a concentration of the 5-methylthioadenosine in said cell culture medium is from about 10 nM to about 200 nM; andwherein the supplementation with 5-methylthioadenosine increases a titer of said aflibercept.2. The method of claim 1 , wherein the titer of said aflibercept is at least about 2% greater than another method with a cell culture medium that has less than 10 nM of 5-methylthioadenosine.3. The method of claim 1 , wherein the cell culture medium further comprises one or more acids selected from lactic acid claim 1 , phenyllactic acid claim 1 , indolelactic acid claim 1 , succinic acid claim 1 , alpha-hydroxyisovaleric acid claim 1 , alpha-hydroxyisocaproic acid claim 1 , 2-(4-hydroxyphenyl)lactic acid claim 1 , or 2-hydroxy-3-methylvaleric acid claim 1 , salts of these acids claim 1 , esters of these acids and combinations thereof.4. The method of claim 1 , wherein the eukaryotic cells include at least one selected from the group consisting of: baby hamster kidney cell lines claim 1 , Chinese hamster ovary cell lines claim 1 , murine myeloma cell lines claim 1 , mouse myeloma cell lines claim 1 , human embryonic kidney cell lines claim 1 , human retina-derived cell lines claim 1 , and amniocyte cell lines.5. The method of claim 1 , wherein the aflibercept is secreted in the medium.6. The method of claim 1 , wherein the cell culture medium does not have a protein derived from an animal having a pH between 6.5 and 8.0.7. The method of claim 1 , wherein the cell culture medium is a serum-free medium having a pH between 6.5 and 8.0.8. The method of claim 1 , wherein the cell culture medium is a ...

Подробнее
09-06-2022 дата публикации

METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF

Номер: US20220177842A1
Принадлежит:

The invention relates to a method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast, a human megakaryocyte-erythroid progenitor, or a human common myeloid progenitor, comprising the step of: culturing cells comprising one or more of those cells in a culture medium comprising one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor. 1. A method for long-term ex vivo maintenance or expansion of one or more of a human erythroblast , a human megakaryocyte-erythroid progenitor , or a human common myeloid progenitor , comprising the step of:culturing the cells comprising one or more of the human erythroblast, the human megakaryocyte-erythroid progenitor, or the human common myeloid progenitor in a culture medium, wherein the culture medium comprises one or more selected from a tankyrase inhibitor, a growth factor, a B-Raf kinase inhibitor and a GSK-3 inhibitor.2. The method of claim 1 , wherein the tankyrase inhibitor is one or more of XAV939 claim 1 , AZ-6102 claim 1 , JW-55 claim 1 , MN-64 claim 1 , TC-E 5001 claim 1 , WIKI4 claim 1 , RK-287107 claim 1 , MSC2504877 claim 1 , or G007-LK.3. The method of claim 1 , wherein the concentration of the tankyrase inhibitor in the culture medium is from 0.1 μM to 900 μM.4. The method of claim 3 , wherein the B-Raf kinase inhibitor is one or more of GDC-0879 claim 3 , PLX4032 claim 3 , GSK2118436 claim 3 , L-779450 claim 3 , DABRAFENIB claim 3 , RAF709 claim 3 , BMS-908662 claim 3 , L-779450 claim 3 , LGX818 claim 3 , PLX3603 claim 3 , RAF265 claim 3 , R05185426 claim 3 , vemurafenib claim 3 , PLX8394 claim 3 , or SB590885.5. The method of claim 3 , wherein the GSK-3 inhibitor is one or more of CHIR99021 claim 3 , CHIR98014 claim 3 , LY2090314 claim 3 , ALSTERPAULLONE claim 3 , BIO-ACETOXIME claim 3 , AZD1080 claim 3 , 2-D08 claim 3 , SB216763 claim 3 , BIO claim 3 , SB415286 claim 3 , TWS119 claim 3 , Tideglusib claim 3 , A1070722 claim 3 ...

Подробнее
27-04-2017 дата публикации

Pluripotent cell lines and methods of use thereof

Номер: US20170114324A1

Methods of generating cell lines with a sequence variation or copy number variation of a gene of interest, methods of use thereof, and cell lines with a sequence variation or copy number variation of a gene of interest are provided.

Подробнее
09-04-2020 дата публикации

CELL SHEET CONSTRUCT FOR NEUROVASCULAR RECONSTRUCTION AND MANUFACTURE THEREOF

Номер: US20200108176A1
Принадлежит:

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct. 1. A method for manufacturing a cell sheet construct , consisting of:step 1. culturing vascular endothelial cells on a cell culture dish with a vascular endothelial cell medium to form a vascular endothelial cell layer;step 2. seeding neural stem cells on the vascular endothelial cell layer to ensure the neural stem cells being physically in direct contact with the vascular endothelial cell layer;step 3. co-culturing the neural stem cells and the endothelial cell layer to form a cell sheet construct of neural stem cells-vascular endothelial cells (NSC-EC);step 4. detaching the cell sheet construct of NSC-EC from the culture dish and transferring the same to a cell culture surface; andstep 5. culturing the cell sheet construct of NSC-EC with a NSC-EC co-culture medium.2. The method of claim 1 , wherein the neural stem cells are human cerebral neural stem cell line claim 1 , SCC007 claim 1 , Millipore.3. The method of claim 1 , wherein the vascular endothelial cell layer is used as a carrier.4. The method of claim 1 , wherein in step 1 claim 1 , the cell culture dish ...

Подробнее
09-04-2020 дата публикации

Cell sheet construct for neurovascular reconstruction and manufacture thereof

Номер: US20200108177A1
Принадлежит: NATIONAL DEFENSE MEDICAL CENTER

The invention relates to a cell sheet construct for neurovascular reconstruction. The cell sheet construct has a vascular endothelial cell layer and a neural stem cell layer, and the two layers are physically in direct contact with each other, where the vascular endothelial cell layer forms branching vasculatures, and the neural stem cell layer differentiates into neurons. The invention also relates to a method for manufacturing the cell sheet construct, having the following steps: culturing vascular endothelial cells on a substrate to form a vascular endothelial cell layer, seeding neural stem cells on the vascular endothelial cell layer to make the neural stem cells be physically in direct contact with the vascular endothelial cell layer, and culturing the neural stem cells and the vascular endothelial cell layer to differentiate into neurons and branching vasculatures to form a cell sheet construct.

Подробнее
25-08-2022 дата публикации

Sphingolipids for generating regulatory cd4+ t cells

Номер: US20220265713A1
Автор: Guoliang CUI, Sicong MA
Принадлежит: Deutsches Krebsforschungszentrum DKFZ

The present invention relates to a substance of formula (I), whereby R1 is an alkyl or alkenyl group having 6 to 20 carbon atoms; R2 is H or missing, whereby O is bound via a double bond, R3 is H or an acyl group -C(O)R5, whereby R5 is an alkyl or alkylene group having 1 to 10 carbon atoms, and R4 is H or a phosphate group for use as a medicament and for use in a method of preventing or treating a subject suffering from an autoimmune disease. The present invention further relates to a method for generating regulatory T cells (Treg cells) in vitro comprising the steps of providing precursor CD4+T cells, cultivating the precursor CD4+T cells provided in step 1) in the presence of the substance as defined herein, and, optionally, isolating the generated regulatory T cells (Treg cells).

Подробнее
04-05-2017 дата публикации

ARYL HYDROCARBON RECEPTOR DISRUPTION AND ENHANCEMENT

Номер: US20170121683A1
Принадлежит:

Methods for enhancing and disrupting activity of the aryl hydrocarbon receptor (AHR) and cells having disrupted or enhanced AHR activity. The methods and cells may be used to enhance production of specific cell populations during hemato-endothelial cell or hemato-lymphoid cell development. 2. The method of claim 1 , wherein the hemato-endothelial cell comprises at least one of an endothelial cell (EC) claim 1 , a CD34CD31 cell claim 1 , or a CD34CD144 cell.3. The method of claim 1 , wherein hematopoietic progenitor cell comprises at least one of a CD34CD43 cell and a CD34CD45 cell.4. The method of claim 1 , wherein the hemato-lymphoid cell comprises a conventional natural killer (cNK) cell.5. The method of claim 1 , wherein disrupting AHR activity comprises treating the cell with an aryl hydrocarbon receptor (AHR) antagonist.6. The method of claim 5 , wherein the AHR antagonist comprises StemReginin-1 (SR-1).7. The method of claim 1 , wherein disrupting AHR activity comprises reducing expression of AHR in the cell.8. The method of claim 7 , wherein the reduction of expression of AHR is inducible.9. The method of claim 1 , wherein the stem cell is an embryonic stem cell or an induced pluripotent stem cell (iPSC).10. The method of claim 1 , wherein the method further comprises treating the cell with media comprising at least one of IL-15 claim 1 , IL-7 claim 1 , Flt-3 ligand claim 1 , stem cell factor claim 1 , and IL-3.11. A hemato-endothelial cell claim 1 , a hematopoietic progenitor cell claim 1 , or a hemato-lymphoid cell derived from the methods according to .13. The method of claim 12 , wherein the ILC3 cell is at least one of CD94 claim 12 , CD117 claim 12 , CD56 claim 12 , and LFA1.14. The method of claim 12 , wherein enhancing AHR activity comprises treating the cell with an AHR agonist.15. The method of claim 14 , wherein the AHR agonist comprises tetrachlorodibenzo-p-dioxin (TCDD).16. The method of claim 12 , wherein enhancing AHR activity comprises ...

Подробнее
14-05-2015 дата публикации

ENCAPSULATION AND CARDIAC DIFFERENTIATION OF hiPSCs IN 3D PEG-FIBRINOGEN HYDROGELS

Номер: US20150132847A1
Принадлежит:

The present invention relates to the production of cell cultures and tissues from undifferentiated pluripotent stem cells using three-dimensional biomimetic materials. The resultant cell cultures or tissues can be used in any of a number of protocols including testing chemicals, compounds, and drugs. Further, the methods and compositions of the present invention further provide viable cell sources and novel cell delivery platforms that allow for replacement of diseased tissue and engraftment of new cardiomyocytes from a readily available in vitro source. The present invention includes novel methods required for the successful production of cell cultures and tissues, systems and components used for the same, and methods of using the resultant cell and tissue compositions. 1. A method of producing a three-dimensional cell culture or tissue comprising:combining a population of pluripotent stem cells (PSCs) with a biomimetic material to form a biomimetic-PSC suspension;treating said biomimetic-PSC suspension to produce a three-dimensional biomimetic-PSC microenvironment; andculturing said biomimetic-PSC microenvironment to differentiate the PSCs into at least one type of somatic cell.2. The method of wherein the biomimetic material is a hydrogel.3. The method of wherein the hydrogel is a covalently-linkable hydrogel.4. The method of wherein the covalently-linkable hydrogel is a PEG-based hydrogel.5. The method of wherein the PEG-based hydrogel comprises PEG-fibrinogen.6. The method of wherein said treating said biomimetic-PSC suspension further comprises placing said biomimetic-PSC suspension into a mold.7. The method of wherein said microenvironment is selected from the group consisting of microislands claim 1 , cardiac discs claim 1 , strings claim 1 , macrotissues claim 1 , and microspheres claim 1 , and combinations thereof.8. The method of wherein said treating said biomimetic-PSC suspension to produce a three-dimensional biomimetic-PSC microenvironment comprises ...

Подробнее
14-05-2015 дата публикации

TISSUE CULTURING METHOD, CULTURING METHOD OF FERNS AND EXPLANT OBTAINED THEREFROM

Номер: US20150132852A1
Принадлежит: Chunghwa Picture Tubes, LTD.

A tissue culturing method includes following steps: providing a chopped gametophyte, generating calluses by culturing the chopped gametophyte, and performing apogamic regeneration of sporophytes, by culturing the calluses in a culture fluid to develop the sporophytes from the calluses. The present invention also provides a tissue culturing method of ferns and an explant. 1. A culturing method of ferns , comprising:providing a chopped gametophyte of ferns;generating a callus, by culturing the chopped gametophyte of ferns till the chopped gametophyte generates the callus; andperforming apogamic regeneration of a sporophyte, by culturing the calluses in a culture fluid to develop the sporophyte from the callus.2. A tissue culturing method , comprising following steps:providing a chopped gametophyte;generating a callus, by culturing the chopped gametophyte till the chopped gametophyte generates the callus; andperforming apogamic regeneration of a sporophyte, by culturing the calluses in a culture fluid to develop the sporophyte from the callus.3. The tissue culturing method of claim 2 , wherein the step of generating the callus further comprises inducing the chopped gametophyte to generate the callus and proliferating a generated callus.4. The tissue culturing method of claim 2 , wherein the step of apogamic regeneration of the sporophyte further comprises sporophyte induction claim 2 , by inducing the callus to form the sporophyte claim 2 , and sporophyte proliferation claim 2 , by proliferating a formed sporophyte.5. The tissue culturing method of claim 2 , wherein the culture fluid comprises 1 wt % to 5 wt % carbon source.6. The tissue culturing method of claim 2 , wherein the culture fluid comprises ½ MS medium and 20 g/L sucrose.7. The tissue culturing method of claim 2 , wherein the step of apogamic regenerating the sporophyte comprises culturing the callus in a first culture fluid to induce the generating of the sporophyte from the callus claim 2 , and then ...

Подробнее